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Chapter 1 — Introduction
Background and Significance
Cancer Survivorship
Cancer is a major public health problem. In 2009 there were an estimated 11 million
cancer survivors in the United States. Cancer is the leading cause of death among
women 40 to 79 yr and men 60 to 79 yr. The most common forms of cancer among men
are prostate, lung, and colorectal cancer with rates of 158.2, 87.3, and 61.2 diagnoses
per 100,000 persons, respectively.

The cancer incidence rate among White non-

Hispanic men is 551 diagnoses per 100,000 people compared to African American men
with 652 diagnoses per 100,000 people. The most common forms of cancer among
women are breast, lung, and colorectal with rates of 123.6, 55.4, and 44.8 diagnoses per
100,000 persons, respectively. White non-Hispanic women are at higher risk for
developing cancer with 423 diagnoses per 100,000 people compared to African
American women with 398 diagnoses per 100,000 people.

Cancers of the breast,

prostate, lung, and colon accounted for an estimated 751,061 new diagnoses (~50% of
all cancer diagnoses) and 276,000 deaths (~49% of all cancer related deaths) in 2009 in
the United States. The lifetime probability of developing cancer for men is 50% (1 in 2)
and for women 38% (~1 in 3) (1).
Despite high incidence rates among the general population, advances in
screening, surgical procedures, and pharmacological interventions have increased the 5
yr survival rate among all cancers survivors from 50% in 1974 to 66% in 2009 (1). This
16% increase equates to ~1.7 million people living with cancer for ≥5 yr after diagnosis
in 2004 that if diagnosed in 1969 may have not been alive in 1974 (1).
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While living longer after diagnosis, cancer survivors frequently report physical
and psychological symptoms associated with cancer or cancer treatment(s) including
loss of appetite, nausea, difficulty concentrating, fatigue, and depression (2). Nearly all
cancer survivors report one or more symptoms affecting their sense of well-being that
negatively affects physical and social quality of life (QOL) (3).
Management of symptoms associated with cancer or cancer treatment may have
limited or no treatment so that clinicians are often left with the option of advising their
patients that cancer related symptoms are something they have to learn to live with (3).
However, there is a variety of established interventions to aid in modulating symptom
severity.

These interventions include individual and family counseling, coping skill

development, and communication skill development.

These above-mentioned

interventions broadly focus on improving psychological components of cancer survivor
well-being rather than physical well-being (4, 5). However, in the past two decades,
literature has accumulated that indicates exercise after cancer diagnosis reduces the
incidence and severity of a variety physiologic and psychosocial symptoms’ frequently
reported by cancer survivors. However, the magnitude of symptom improvement among
exercise interventions in cancer survivors is highly variable among individual exercise
interventions. These variations in symptom improvement may due to differences among
exercise interventions including the type of cancer targeted, stage and type of treatment,
type of exercise performed, and the primary health outcomes examined (2, 6).
Exercise Interventions
The accumulation of literature addressing the effect of exercise on symptom
management among cancer survivors has spurred various professional organizations to
develop exercise recommendations tailored for cancer survivors. These organizations
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include the American Cancer Society (7), National Comprehensive Cancer Network (3),
and American College of Sports Medicine (ACSM) (2, 8).

The two sets of ACSM

exercise guidelines were developed differently; one in the form of guidelines based on
limited literature-based evidence (8), and the other, an expert panel consensus (2). A
noteworthy comment, each exercise recommendation from the American Cancer
Society, National Comprehensive Cancer Network and the ACSM suggest different
“Exercise Prescription’s (Ex Rx)” elicit favorable outcomes among cancer survivors. For
example, the American Cancer Society and National Comprehensive Cancer Society
make no recommendation of resistance training among cancer survivors, whereas the
ACSM suggests resistance training performed two days per week to achieve the healthbenefits associated with exercise.
The current professional exercise recommendations for cancer survivors (2, 3, 7,
8) are generic, in that one set of recommendations is used for all cancer survivors.
However, due to the variety of cancers, their varying pathophysiology, and varying
treatment regimes, Ex Rx’s may need tailoring specific to the health outcome of interest
(i.e., reducing depression) for the most efficacious benefits of exercise to be achieved
(8). The components of any Ex Rx are frequency (F), intensity (I), time (T), and type (T)
of exercise performed, labeled the FITT principle of Ex Rx (8). Frequency refers to how
often the exercise sessions take place (i.e., 2 d∙wk-1). Intensity refers to how hard or the
level of physical exertion is (i.e., low, moderate, or vigorous). Intensity of exercise can
be quantified using metabolic equivalent units (METs). One MET is equal to 3.5 ml∙kg∙min-1, representing oxygen consumption (ml) per kg of body weight per minute while
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sitting quietly. METs are categorized into light intensity (<3 METs), moderate intensity (3
to 6 METs), or vigorous intensity (>6 METs). Time refers to how long each exercise
session is (i.e., 30 min∙d-1). Type refers to the modality or kind of activity completed (i.e.,
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cycling, walking, weight training).
ACSM’s Guidelines for Exercise Testing and Prescription, eighth edition (8)
provide the most detailed FITT recommendations for cancer survivors.
recommendations

focus

on

a

balanced

health-fitness

program

These

consisting

of

cardiovascular fitness, muscular strength, muscular endurance, and flexibility activities
(8).

These guidelines suggest moderate-intensity aerobic and resistance exercise,

complimented with flexibility exercise (Table 1) are appropriate for the general physical
and mental health of cancer survivors.

However, this FITT Ex Rx is not symptom

specific and thus, may not be the most effective FITT when attempting to maximize the
modulation of specific symptoms and health outcomes of cancer survivors.
Table 1. American College of Sports Medicine Exercise Guidelines for Cancer Survivors
(8)
Modality

Frequency

Intensity

Time

Aerobic

3-5 d∙wk-1

40–60% V02R
3-6 MET

20-60 min∙d-1

1-3 Sets
8-12
Repetitions
10-30 Seconds
Flexibility
Tension
2-7 d∙wk-1
4 Repetitions
MET: Metabolic equivalent, 1 MET = 3.5 ml·kg-1·min-1.
V02R: Maximal Oxygen Consumption Reserve.
1RM: 1 Repetition Maximum.
Resistance

2-3 d∙wk-1

40-60% 1RM
<3 MET

Type
Walking
Cycling
Swimming
Weight Machines
Stretching

The panel of ACSM exercise experts among cancer survivors (2) advised cancer
survivors to follow the recommendations set forth by the American Cancer Society (7).
The American Cancer Society guidelines emphasize cancer survivors accumulate ≥150
min∙wk-1 of aerobic exercise and make no mention of resistance training or flexibility
exercise (7). The ACSM expert panel recommended in addition to the American Cancer
Society Guidelines of 150 min∙wk-1 of aerobic exercise (7), moderate intensity,
resistance and flexibility exercise be performed to achieve the general health benefits
4

associated with exercise among cancer survivors. The expert panel concluded exercise
is safe among cancer survivors during and after completion of primary pharmacological
treatment (i.e., radiation, chemotherapy). However, the panel acknowledged there are
considerable gaps in the dose of exercise most effective in reducing the incidence and
severity of specific symptoms associated with cancer or cancer treatment. Similar to the
ACSM expert consensus statement (2), the National Comprehensive Cancer Network
and American Cancer Society suggest accumulating 150 min∙wk-1 of aerobic exercise is
efficacious to achieve the health related benefits of exercise specific to cancer survivors
(3, 7). However, these guidelines set forth by the ACSM (2, 8) are a general framework
that may require adaptation and tailoring as appropriate for the cancer survivor based on
disease and functional status, and presence of other comorbidities (2).
Cancer-Related Symptoms and Side Effects
Cancer-Related Fatigue (CRF)
CRF is the most frequent symptom experienced by 70-100% of all cancer survivors (9).
CRF is as a distressing, persistent, subjective sense of physical, emotional, and/or
cognitive tiredness or exhaustion related to cancer and/or cancer treatment (3). The
magnitude of CRF is not proportional to recent activity and may interfere with usual
functioning and QOL (3). CRF should not to be confused with general fatigue. General
fatigue differs from CRF in general fatigue is proportional to recent activity and is usually
relieved after rest periods of sleep. In contrast, the magnitude of CRF does not diminish
after a rest period of sleep and may persist for weeks or even years (3).
van den Beuken-van Everdingen et al. (10) surveyed 1,429 cancer patients at 11
cancer treatment centers.

The primary aims of this study were to: (i) measure the

prevalence of symptoms related to all types of cancer; (ii) determine the impact
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symptoms have on QOL; and (iii) inquire whether patients receive treatment for their
complaints/symptoms. Patients were diagnosed with a variety of cancer types, most
commonly breast (24%) followed by colorectal (14%), prostate (13%), and lung (5%) in
all stages of treatment. The symptoms “need to rest” and “tiredness” were the most
commonly reported symptoms when compared to all other symptoms associated with
any type of cancer (Table 2). The symptoms “need to rest” and “tiredness” did not
appear to diminish after completion of curative treatment and affected survivors
regardless of treatment status. The symptoms “need to rest” and “tiredness” diminished
QOL among this sample (β = -0.261, p < .001) (10).
Table 2. Most Commonly Reported Symptoms in Cancer Survivors (10)
Treatment Stage
Symptoms
“Need to rest”
“Tiredness”
≥ 6 months after curative treatment (n = 384)*
24% (n = 92)
28% (n = 107)
*
≤ 6 months after curative treatment (n = 384)
36% (n = 138)
36% (n = 138)
Palliative Therapy (n = 571)**
43% (n = 245)
45% (n = 256)
*
Includes treatments chemotherapy, radiation therapy, hormone therapy, and bone
marrow transplant procedures.
**Includes treatments of physical or occupational therapy, psychosocial counseling, and
hormone therapy.

Despite the growing literature examining CRF, outcomes have varied
considerably, ranging from one-fold increases in CRF to two-fold reductions from
baseline in response to exercise (11). In addition to the previously discussed literature,
five meta-analyses examining the role of exercise in the modulation in CRF have
quantified the high variability in randomized controlled exercise trials examining CRF (6,
11-14).

Three of these meta-analyses (11, 13, 14) examined CRF moderators or

variables that may influence the magnitude of CRF reduction in response to exercise.
Moderators included type of cancer, a CRF driven hypothesis, methodological quality,
and supervision of exercise sessions. Breast cancer survivors decreased CRF more
than non-breast cancer survivors (11, 13, 14). Exercise interventions with an ‘a priori’
6

CRF related hypothesis achieved greater reductions in CRF than studies without an a
priori CRF hypothesis, and studies of lower methodological quality reduced CRF more
than exercise interventions of higher methodological quality (14). However, no metaanalysis has examined the Ex Rx FITT components as they modulate CRF among adult
cancer survivors. Further, no meta-analysis has examined any potential interactions
between the Ex Rx FITT components and clinical characteristics of cancer survivors
(i.e., the interaction of stage of treatment with intensity of exercise and the subsequent
modulation on CRF).
Depression
Sixteen to 60% of cancer survivors experience depression (15). Depression among
cancer survivors may constitute any of the following symptoms: recurrent feeling or
thought of death, changes in body image, negative self-esteem or societal role or
lifestyle changes, or concern over money and legal matters (16). Prior to treatment,
cancer survivors experiencing less depression had a lower incidence and severity of
depression at 5 yr follow-up than cancer survivors reporting more depression prior to
treatment (4).
The use of physical activity as a non-pharmacological modality to aid in the
treatment of depression or depression-related symptoms among healthy populations has
been investigated for more than a century (17).

Meta-analyses of prospective

intervention studies examining the effects of exercise and depression have supported
the use of exercise as a non-pharmacological modality to reduce depression among
apparently healthy populations, with small to moderate sized standardized mean
reductions (18, 19).

These meta-analyses (18, 19) have examined moderators of

exercise related reductions in depression including age, length of the exercise
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intervention, exercise modality, and type of depression questionnaire used. Lawlor et al.
(18) meta-analyzed 14 exercise interventions among men and women aged 24 to 88,
apparently healthy population only diagnosed with clinical depression.

They found

studies with a shorter exercise intervention length were more efficacious in reducing
depression than standard care.

Conn et al. (19) meta-analyzed 60 exercise

interventions among non-cancer survivors, apparently healthy population only diagnosed
depression, and concluded studies providing low intensity, aerobic exercise reduced
depression to the greatest extent. Additional moderators identified by Conn et al. (19)
included methodological considerations relating to random assignment and control group
management, with studies of higher methodological rigor reducing depression to a lesser
extent than studies of poor methodological quality. Additionally, studies providing a true
control group reducing depression more than studies providing a placebo, attention
control (19).
Despite a large majority of research examining the efficacy of exercise in
apparently healthy populations, there is emerging observational and interventional
researching examining exercise and depression among cancer survivors. Chen et al.
(20) observed 1,399 women diagnosed with stage 0 to III breast cancer. Concluding
women with higher exercise levels (≥8.3 MET h∙wk-1) were less likely to have depression
at 18 months post diagnosis; the multivariate adjusted odds ratio was 0.56 (95% CI 0.35
to 0.88). Yet, contrary to observational studies, prospective exercise intervention studies
exhibit moderate to large amounts of heterogeneity among RCTs with improvements in
depression ranging from negligible to three-fold improvements relative to baseline (6,
12).
Due to the high variability between individual prospective RCTs, two metaanalyses have examined the standardized mean exercise-related reduction of
8

depression among cancer survivors (6, 12). Schmitz et al. (6) and Speck et al. (12)
concluded evidence is suggestive, but not statistically significant effects, of exercise
providing a small reduction in depression among cancer survivors (standardized mean
reductions of 0.20 and 0.30, respectively).

Due to small sample sizes of six (6) and

seven (12) studies, these meta-analyses may have lacked sufficient statistical power to
detect a significant effect in the exercise-induced reduction of depression. In addition,
Speck et al. (12) reported statistically significant heterogeneity of 85% among
depression outcomes. Despite the heterogeneity between studies in this meta-analysis,
neither (6, 12) examined moderators of the exercise related reduction of depression
among cancer survivors.

Lack of moderator analyses in these studies (6, 12) is a

research gap in the literature. There is high variability between individual exercise trials
with respect to varying Ex Rx characteristics, and clinical cancer survivor characteristics
making moderator analysis appropriate to perform (6, 12).
In summary, cancer survivors are clinically heterogeneous with respect to
demographic characteristics (i.e., gender, age at diagnosis), disease pathophysiology
(i.e., type of cancer, tumor location, and staging), treatment protocols, and symptoms
and side effects impairing activities of daily living (2). Clinical characteristics specific to
each cancer survivor may influence the efficacy of an exercise intervention on CRF and
depression outcomes (5, 13, 14). For example, type of cancer has been shown to be
predictive of QOL levels, with gastrointestinal and gynecologic cancer survivors
experiencing lower QOL relative to lung, breast and prostate cancer survivors among
others (β = -4.490, β=2.202, p<.001, respectively) (10). Therefore, the purpose of this
research is to meta-analytically investigate the influence of clinical (i.e., type of
treatment, tumor location, and staging) and demographic characteristics (i.e., gender,
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ethnicity, and age) individually, as well as their interactions with Ex Rx FITT
characteristics on CRF and depression modulation among cancer survivors.
Meta-Analysis
Meta-analysis or quantitative reviewing of the literature is the combining of
numerical results of individual studies to generate a “summary” result. In the context of
this research the effect of the Ex Rx FITT characteristics effects on the modulation of
CRF and depression among cancer survivors.

Another purpose of the study is to

examine the extent to which clinical characteristics moderate the exercise-induced
reductions in depression. Further, we will examine interactions among the Ex Rx FITT
characteristics and clinical characteristics influencing the efficacy of exercise to reduce
CRF and depression among adult cancer survivors. Findings from this analysis may
provide guidance as to what specific FITT Ex Rx may prove most efficacious for cancer
survivors suffering from CRF and depression.
Specific Aims and Hypotheses
The primary aims of this study are:
Specific Aim 1. To meta-analyze the literature to determine the efficacy of exercise
interventions on reductions in CRF and depression among cancer survivors.
Hypothesis 1. Cancer survivors engaging in exercise will demonstrate a statistically
significant reduction in CRF and depression when compared to non-exercising controls.
Specific Aim 2. To meta-analyze the literature to examine the influence of the Ex Rx
FITT components on reductions in CRF and depression among cancer survivors.
Hypothesis 2. Ex Rx FITT components will modulate the magnitude of the reduction in
CRF and depression.
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Specific Aim 3.

To meta-analyze the literature to examine the influence of patient

clinical characteristics (i.e., cancer type, treatment staging, and age) on reductions in
CRF and depression among cancer survivors.
Hypothesis 3. Patient clinical characteristics of cancer survivors will modulate the
magnitude of the reduction in CRF and depression that result from exercise.
Specific Aim 4.

To meta-analyze the literature to examine the influence of the

interactions among Ex Rx FITT components (specific aim 2 & hypothesis 2) and patient
clinical characteristics (specific aim 3 & hypothesis 3) on reductions in CRF and
depression among cancer survivors.
Hypothesis 4. The interactions among Ex Rx FITT components and patient clinical
characteristics will modulate the magnitude of the reduction among cancer survivors.

B.

Significance

Cancer is a disease of global impact with an estimated 25 million cancer survivors
worldwide (21). Globally, the World Health Organization (WHO) has assembled a panel
of cancer experts to develop long-term cancer goals and objectives (21). Specifically the
WHO has established goals for cancer survivorship. The specific WHO goals are to
increase the QOL among those living with cancer, and to provide relief from pain and
other distressing symptoms among all survivors of cancer. The long-term goal of the
WHO is to establish National Cancer Control Programs for holistic cancer guidance in all
countries, worldwide (21).
Nationally, the US has developed 10 yr health and disease prevention goals and
objectives (22). The two over-arching goals of Healthy People 2010 were to increase
quality and years of health life, and to eliminate health disparities. Healthy People 2010
included a target area specific to cancer, addressing a variety of screening, treatment
and long-term survivorship goals. Specific to this research project, goal three, objective
11

15, was to increase the proportion of cancer survivors who are living 5 yr or longer after
diagnosis to 70%. Healthy People 2010 failed to reach the target set at 70%, but did
increase 5 yr survivorship to 64%.

Despite not reaching the objective of 70%, the

percentage of cancer survivors living ≥5 yr after diagnosis did increase by 45% from
year 2000. Increasing 5 yr survivorship among cancer survivors has been a renewed
objective in Healthy People 2020 (22). The desired percentage of cancer survivors living
≥5 yr after diagnosis for Healthy People 2020 is 76%.
The clinical significance of this research is two-fold. No study to date has metaanalyzed exercise intervention FITT Ex Rx characteristics that influence CRF and
depression among cancer survivors. This study may provide further support for the use
of exercise as a non-pharmacological modality for clinicians to recommend to cancer
survivors with CRF and depression. This study may also provide quantitative evidence
for the use of specific Ex Rx FITT recommendations targeted to those patients suffering
with CRF or depression based on desired health outcome and clinical characteristics.
In summary, the purpose of this research is to quantitatively summarize the effect
of exercise on the modulation of CRF and depression among cancer survivors and
generate hypotheses for future research. Quantitatively summarizing the literature on
exercise and cancer survivorship will shape future exercise interventions, and more
importantly, improve current palliative care practices for those cancer survivors currently
living with CRF and depression.
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Chapter 2 — Methods

We investigated the variability in FITT Ex Rx and the extent to which exercise modulated
CRF and depression among cancer survivors using meta-analytic techniques.

This

chapter describes the procedures used for the meta-analysis including the literature
search, initial screening of studies, full-text review, data extraction, calculation of study
level effect size, calculation of the pooled effect, tests for heterogeneity, publication bias,
and meta-regression techniques.
Literature Search
Types of participants:

Studies considered for inclusion investigated the use of

exercise in attempt to modulate CRF or depression levels in adults 18 yr or older. We
included both, men and women, all cancer types, stages of cancer, and types of cancer
treatment.

Subjects were currently receiving treatment, in long-term follow-up, or

receiving palliative care.
Types of interventions: Studies considered for inclusion evaluated and reported the
effect of exercise on CRF or depression levels in cancer survivors. Studies compared
an exercise intervention group to a non-exercise, usual care group, or compared an
exercise group to an alternative non-physical intervention such as audio therapy or
aroma therapy. The exercise intervention occurred in any setting; home, public location,
or medical center. Exercise interventions may have been conducted in group-format
(e.g., group exercise classes) or individually (i.e., personal training). All modalities of
exercise were considered for inclusion (i.e., aerobic, strength, neuromotor, and flexibility
exercises).
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Types of outcome measures: The primary outcome measures were self-reported CRF
or depression levels.

To be included, assessment of CRF and depression levels

occurred at the start of the exercise intervention and at completion, for each group,
intervention and control, respectively.
Search methods for identifying relevant studies:

The following databases were

searched for relevant studies to be included in this meta-analysis; MEDLINE; The
Cochrane Controlled Trials Register; PsycINFO, Dissertation Abstracts International,
and OregonPDF in Health and Human Performance. The CRF systematic search ended
February 2010, and the depression systematic search ended December 2010. Citation
lists of all relevant literature were reviewed for additional studies and journals relating to
cancer survivors were searched (i.e., Journal of Cancer Survivorship). There were no
language restrictions when attempting to locate studies for inclusion. Searches included
medical subject headings (MeSH) to conduct the systematic literature search (Figure 1).
Screening of all studies in the comprehensive literature search were completed
by reviewing the title and abstract for inclusion criteria. Reviewers (i.e., JB and SP) were
not blinded to journal title or author. The reviewers (JB, SP) screened both title and
abstract for inclusion in this meta-analysis. To ensure proper screening, approximately
10% of all excluded studies were re-screened to validate inclusion/exclusion of
appropriate literature.
The inclusion criteria included RCTs that use an exercise intervention compared
to a usual care, or non-exercising control group with CRF or depression measured as an
outcome variable.

The intervention took place in adults of any age, caner type,

treatment stage, or other demographic characteristics.
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Data Extraction:

After appropriate title and abstract screening, the literature was

subject to a full-text review.

Studies reviewed were issued a unique identification

number to ensure organization and quality control.

After full-text review, if studies

continued to meet the inclusion/exclusion criteria, data were extracted via a
comprehensive coding form (see Appendix). Data extracted included information on
subject demographics (e.g., age, gender, socioeconomic status), study design
characteristics (i.e., randomization and blinding procedures, length of exercise
intervention, and location of exercise intervention), and subject cancer characteristics
(e.g., cancer type, treatment type, and time length since diagnosis). Characteristics
regarding the FITT Ex Rx employed were also extracted.

Specifically, how often

(frequency), how hard (intensity), time (duration) and mode (type) of exercise were
extracted. Intensity of exercise was coded in metabolic equivalent units (METs) using
the compendium of MET intensities (1). This compendium is valid and widely used in
physical activity disciplines for coding absolute energy expenditures.
Data Extraction Agreement:

Kappa statistic and Pearson’s r assessed individual

coder agreement for categorical variables and continuous variables, respectively. The
Kappa statistic accounts for the degree of chance occurrence agreement between the
two coders. This statistic provides information on the reliability and reproducibility of the
coders, and accounts for the degree of chance occurrence between coders in addition to
actual agreement (2). Superior to simply calculating percent agreement, the Kappa
statistic ensures quality control in data extraction.
The guidelines for interpreting the Kappa statistic were <0 = poor, 0.00-0.20 =
slight, 0.21-0.40 = fair, 0.41-0.60 = moderate, 0.61-0.80 = substantial, and 0.81-1.00 =
almost perfect agreement (2, 3). Even in the presence of substantial or almost perfect
agreement, the Kappa statistic may appear low, ranging from 0.61-1.00, respectively.
17

The guidelines for interpreting Pearson’s r were 0.00-0.49 = low to no agreement, 0.500.79 = moderate or medium agreement, 0.80-1.00, strong, or perfect agreement (2).
The Kappa statistic was applied to categorical study dimensions and Pearson’s r was
applied to continuous study dimensions.
Individual Effect Size Estimates: Because the majority of randomized controlled trials
(RCTs) reported continuous measures of CRF and depression, standardized mean
difference effect sizes were used. Effect sizes were used to estimate the efficacy of the
FITT Ex Rx on the modulation of CRF and depression.

The standardized mean

difference effect size (d) was the mean difference between the treatment and control
groups divided by the pooled standard deviation (4). The effect size d has a slight bias
tending to overestimate the true population mean ( ) when studies have small sample
sizes. We removed this bias by applying a correction factor that yields an unbiased
estimate of ( ) (5).
0.035% when df

Applying this correction yielded an error <0.007 and less than

10 (6).

This application was applied to all effect sizes prior to

analysis. CRF effect sizes are positive when the treatment group reduced their fatigue
more when compared to the usual care group. Depression effect sizes are negative
when the treatment group reduced their depression more when compared to the usual
care group. Some studies included more than one treatment group. In this situation, we
compared each treatment group to the control group, producing two effect size estimates
from one study (7).
Mean Effect Size Calculation (Fixed Effects vs. Random Effects)
Fixed Effects Modeling: The overall estimate of the effect was calculated using two
models for each CRF and depression outcomes. The first, a fixed effect model assumed
all studies in the meta-analysis were treated as sharing a common effect size.
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All

factors that could influence the effect size were the same in all studies. Each individual
study was assigned a weight. This weight corresponded to the inverse within study
variance.
Random Effects Modeling: In a random-effects model, as with a fixed effects model,
each study was weighted by the inverse of its variance. The difference between fixed
and random effects model was that the weighting not only included within study variance
(as seen with fixed-effects assumptions) but the between study variance as well,
denoted

2

(tau-squared). Random effects modeling provided wider confidence intervals

around the mean effect size, due to added between study variance.
Fixed vs. Random Effects Modeling: The mean effect was the weighted average of
the means of individual study effects. We implemented both the fixed and random
effects models in our analysis to calculate the mean effect. These values provided an
estimate on the efficacy of CRF and depression modulation in repose to an exercise
intervention.
Publication Bias: We examined both forest and funnel plots for publication bias. These
graphical techniques illustrated the variability among sampled studies (forest plot) and
the expected effect size (funnel plot) by plotting calculated effect size against variance.
We also assessed publication bias statistically via Begg and Egger publication bias
methods (6) and the non-parametric “Trim and Fill” method, a non-parametric test for
asymmetry in the distribution of effect sizes (8).
Heterogeneity: The homogeneity in effect sizes measured the differences of similarities
between studies (9). Homogeneity (Q) was then calculated to determine if there was
more variance between studies than would be produced by random sampling alone. Q is
not a standardized statistic, making its interpretation difficult in a given context. Q was
19

then transformed to I2, a standardized measure of homogeneity. I2 values assumed a
range of 0-100%, indicating homogeneity (0%) or heterogeneity (100%) between studies
(9).
Meta-Regression: Moderators (i.e. covariates) were tested with the FITT Ex Rx and
clinical characteristics with respect to CRF or depression outcomes, respectively.
Specific

subject

demographic

characteristics

were

also

examined.

Specific

characteristics included age, gender, ethnicity, socioeconomic status, education, type of
cancer, type of treatment, stage of treatment, and time since diagnosis. Moderators
listed above were also included within the comprehensive coding form (Appendix A).
Statistical Computing: The statistical software package Intercooled Stata version 11.1
(College Station, Texas) performed all statistical analysis (10). Although Stata does not
have built in meta-analytic tools, macros exist for meta-analysis. These macros were
freely downloadable and included: meanes, metareg, metaf, metan, metabias, and
confunnel. Two-sided statistical significance was set at p < 0.05.
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Figure 1. Systematic search terms for CRF and Depression among Cancer Survivors.
Cancer Related Words:
Cancer, Neoplasm, Leukemia, Lymphoma, Radiotherapy,
Chemotherapy, Bone Marrow Transplantation, Tumor, Malignant,
Neutropenia, Carcinoma, Adenocarcinoma

AND
Exercise Related Words:
Exercise, Resistance, Strength, Flexibility, Endurance, Train, Program,
Physical, Activity, Interval, Sport, Performance, Movement, Stretching,
Dance, Tai Chi, Yoga, Walking

AND
Cancer-Related Fatigue Words:
Fatigue, Tired, Weary, Exhaustion, Lackluster, Asthenia, Lack or Loss,
Energy, Vigor, Apathy, Lassitude, Weakness, Lethargy, Feeling,
Drained, Sleepy, Sluggish

OR
Depression Related Words:
Depression, Depressive Disorder, Sad, Worries, Anxious,
Unhappiness, Despair, Hopelessness, Anguish, Misery, Gloom
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Abstract
Background: The purpose of this meta-analysis was to explore the efficacy of exercise
as a non-pharmacological intervention to reduce cancer-related fatigue (CRF) among
adult cancer survivors. We also investigated how different components of the exercise
prescription (Ex Rx), methodological considerations, and subject characteristics
modulate CRF. Methods: A systematic search for randomized controlled trials was
conducted using words related to cancer, exercise, and fatigue. Results: In total 44
studies with 48 interventions qualified, including 3,254 participants of varying cancer
types, stages of diagnosis, treatments, and exercise interventions. Cancer survivors in
exercise interventions reduced their CRF levels to a greater extent than usual care
controls, d+ = 0.31 (95% confidence interval = 0.22 to 0.40), an effect that appeared to
generalize across several types of cancer. CRF levels improved in direct proportion to
the intensity of resistance exercise (β = 0.60, p = .01), a pattern that was stronger in
higher quality studies (β = 0.23, p < .05). CRF levels also reduced to a greater extent
when interventions were theoretically-driven (β = 0.48, p < .001) or cancer survivors
were older (β = 0.24, p = .04).

Conclusions:

Exercise reduced CRF especially in

programs that involved moderate intensity, resistance exercise among older cancer
survivors and that were guided by theory.

Impact:

Our results indicate exercise

interventions for adult cancer survivors should be multi-dimensional and individualized
according to health outcome and cancer type.
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Introduction
Currently, there are over 11-million cancer survivors in the United States (1).
The 5-yr survival rate for cancer survivors has steadily increased from 50% in 1974 to
66% in 2004 (1). Despite living longer after diagnosis, cancer survivors commonly report
having one or more cancer-related symptoms that impact their quality of life and
activities of daily living (2). One of the most commonly reported symptoms by cancer
survivors is cancer-related fatigue (CRF) (3). CRF is a reported side-effect of all types of
cancer treatment (4) affecting nearly 100% of cancer survivors, and persists for years
after treatment cessation (5, 6).

Cancer survivors often state CRF is the most

distressing symptom related to cancer or cancer treatment, more so than pain, nausea,
and vomiting (2, 7, 8).
Cancer survivors often are told by medical providers to learn to live with CRF by
limiting activity, conserving energy expenditure, and relying on others to complete
activities of daily living (3). Yet, new evidence is accumulating that indicates cancer
survivors who engage in exercise experience numerous physical and mental health
benefits including increased functional capacity (4), improved quality of life (9), and
diminished depression (10) and anxiety (10). In addition, meta-analyses (11-14) and
systematic reviews (15) suggest exercise interventions may be moderately efficacious in
modulating CRF.
Despite the promise of exercise in the management of CRF, an exercise
prescription (Ex Rx) tailored for adult cancer survivors experiencing CRF does not exist
(3, 4, 16, 17). The available Ex Rx guidelines for cancer survivors (3, 4, 16, 17) broadly
focus on the general well-being of cancer survivors, encouraging 150 min/wk of aerobic
exercise, 2 d/wk of strength training, and flexibility exercise on days when aerobic or
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resistance exercise is not performed. An American College of Sports Medicine (ACSM)
panel of experts in Ex Rx for cancer survivors recently concluded exercise is safe for
cancer survivors, all cancer survivors should avoid inactivity, and exercise programs
should be adapted for the individual survivor on the basis of health status, cancer
treatment type, targeted health outcomes, and disease trajectory (4). Yet, the panel
acknowledged research in the area of Ex Rx for cancer survivors is in the developmental
stage with significant research gaps in the dose of exercise required to ensure cancer
survivors receive safe and effective Ex Rx for targeted disease end points such as CRF.
We conducted a quantitative review evaluating the efficacy of exercise as an
intervention to reduce CRF among adult cancer survivors. The primary purpose was to
investigate which Ex Rx characteristics were associated with the greatest reductions in
CRF.

We also examined whether study methodological considerations and subject

characteristics combined or interacted with the dose of exercise prescribed to reduce
CRF further.
Methods
Inclusion Criteria
Included were randomized controlled trials (RCTs) that examined the effects of
exercise on CRF in adult patients (≥18 years) diagnosed with any type of cancer, stage
of diagnosis, and type or stage of treatment including those who have completed
treatment.

Exercise interventions may have occurred in any setting with or without

supervision. RCTs may have compared exercise with a usual care group receiving
either (a) standard, usual care (e.g., no exercise program prescribed and to maintain
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current activity levels), or (b) non-exercise related information during the intervention
period.
[See online appendix I for detailed systematic search information]
CRF Outcome Measure
The outcome variable examined was patient-reported CRF (3), which studies
assessed either separately or as a component of a comprehensive psychological
questionnaire with a CRF subscale (see: bottom Table 1) (18-23).
Coding and Reliability
Two independent raters (JB, SP) coded information related to the study (see
Table 1). Intensity of exercise was estimated using metabolic equivalent units (METs),
where 1 MET = 3.5 ml O2·kg-1·min-1. Corresponding MET values for a given exercise
intervention were coded from the Compendium of Physical Activity; these include low
(<3 METs), moderate (3-≥6 METs), and vigorous (>6 METs) intensity levels (24).
Methodological quality was assessed via the Physiotherapy Evidence Database scale
(PEDro). PEDro guidelines categorize high quality studies from 6-11, fair quality 4-5,
and poor quality <4. Reliability of the raters was high across dimensions (M Cohen κ (25)
= 0.78 for categorical variables, M Spearman-Brown reliability (26) = 0.90 for continuous
variables). Disagreements between coders were resolved through discussion.
Study Outcomes and Calculation of Effect Sizes
Because a majority of RCTs reported continuous measures, effect sizes (d) were
defined as the standardized mean difference between the exercise and control groups
divided by the pooled standard deviation, correcting for sample size bias and baseline
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differences (27). Multiple effect sizes were calculated from individual studies when they
included more than one exercise intervention group (e.g., aerobic and resistance training
groups compared to a control group). Subsequent sensitivity analyses were conducted
to confirm the dependence did not influence the mean estimate of the 48 effect sizes
(28). Consequently, the 44 included studies provided 48 exercise vs. control group
comparisons.
[Insert Figure 1 here]
Prior to analysis, data were assessed for publication bias using Begg (29)
(z = 1.01, p = 0.31) and Egger (30) (t = 0.06, p = 0.95) methods, and yielded no
evidence of publication bias (Figure 3 funnel plot, online). The trim-and-fill technique
(31) identified no added or omitted studies were necessary to normalize the effect size
distribution. Analyses were conducted in Stata 10.1 with macros for meta-analysis (32).
The homogeneity statistic, Q, was calculated to determine whether a weighted mean
effect size (d+) characterized a common effect size.

A significant Q indicated the

absence of homogeneity (i.e, more variation in effect sizes than sampling error alone
would predict). To standardize Q, the I2 statistic and its 95% CI were calculated (33, 34).
I2 ranges from 0% to 100% with low values suggesting homogeneity and large values
suggesting heterogeneity. To explain variability in the effect size estimates, the relation
between study-level characteristics and the magnitude of the effects, was examined in
modified least squares regression analysis with the weights equivalent to the variance
for each study effect size (viz., meta-regression). Bivariate analysis was conducted
using fixed-effects assumptions, and the final, multi-moderator analysis was conducted
using random-effects assumptions. To reduce multicollinearity in multiple moderator
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models, all retained continuous moderators were zero-centered, and categorical
variables were contrast coded.
[Insert Table 1 and Table 2 here]
Results
Potentially relevant reports included 7,245 articles of which 44 (N= 3,254)
satisfied the selection criteria. Of the studies identified, 40 provided one CRF effect size
estimate and four studies provided two estimates, yielding 48 effect sizes among 44
studies (See Table 1 for descriptive statistics).

Studies providing two effect sizes

included two independent exercise intervention groups that were compared to one
standard-care group (46, 49, 55, 69).

Three interventions with multiple intervention

groups were randomized to aerobic exercise, resistance exercise, or control condition
(49, 55, 69); whereas the fourth study randomized participants to either supervised
exercise, unsupervised exercise, or a control condition (46). The mean methodological
quality of the 44 included studies was 6.8±1.4 out of 11 (range: 3-10) (Table 2).The
mean age of cancer survivors was 53.8±10.5 yr, and they averaged 6.7±13.8 months
post diagnosis. The majority of cancer survivors were women (86%). Approximately
half (46%) of cancer survivors were currently being treated with primary pharmacological
therapy during the exercise intervention. For those undergoing therapy, a majority of
cancer survivors in the sample (75%) were being treated with a combination of
chemotherapy and radiotherapy, whereas 13% were treated with only chemotherapy,
6% were treated with only radiation, and 6% were treated with only hormone therapy.
Twenty-five studies examined exercise interventions exclusively in breast cancer
survivors (44-55, 57-68), four in prostate cancer survivors (69-72), four in lymphoma (73-
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76), one in leukemia (78), and one in colorectal cancer (77). The remaining nine studies
examined exercise interventions in a mixed group of cancer survivors (35-43). Twentyfour studies included only aerobic exercise (35, 38, 39, 42-44, 46, 49, 50, 52-59, 61, 65,
69, 70, 74, 77, 78), six studies included only resistance exercise (49, 55, 63, 68, 69, 71),
11 studies included a combination of aerobic and resistance exercise (40, 41, 48, 51, 60,
62, 64, 67, 72, 75, 76), and another six included neuromuscular exercise such as tai-chi,
or yoga (36, 37, 45, 47, 66, 73) (Table 5 characteristics of included studies, online).
The average length of the exercise intervention was 11.5±5.2 wk.
survivors exercised 3.5±1.4 d/wk for 48.5±22.8 min/session.

Cancer

The level of physical

exertion or average intensity of the aerobic exercise interventions was 5.6±3.0 METs,
corresponding to moderate intensity exercise (40-60% V02max), and included walking
(48%), stationary cycle ergometry (30%), a combination of walking and cycling (16%), or
other modalities of aerobic exercise such as the elliptical trainer or self-selected (6%).
The average intensity of resistance training was 4.5±2.0 METs, corresponding to
moderate intensity exercise (60-80% one-repetition maximum, 1-RM), and included
weight-machines, resistance bands, or free weights (75%).

The remaining studies

prescribed neuromuscular exercise which commonly included tai-chi or yoga (25%).
Flexibility exercise was a component of the exercise in 52% of exercise interventions.
Supervision of exercise sessions was provided in 60% of the exercise interventions.
Ten studies used a theoretical basis for the exercise intervention (44, 48, 50, 54,
57-59, 61, 62, 65). Three interventions (48, 58, 62) followed the Transtheoretical model
of behavior change (79, 80), two studies (54, 57) followed the model of self-efficacy and
stages of exercise change (81), three studies (50, 59, 61) followed the Roy adaptation
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model (82), one study (44) followed the Payne adaptation model (83) and one study (65)
followed the Levine conservation model (84).
Overall Efficacy of Exercise Interventions on Modulation of CRF
Table 3 summarizes weighted mean effect sizes, d+, for all cancer types
collectively, as well as cancer type individually. This analysis indicated exercise reduced
CRF (Table 3 and Figure 2), yet its impact did not attain significance for survivors of
lymphoma, colorectal, or leukemia cancer, which may have lacked sufficient statistical
power to detect a difference. Pooled, the effect sizes for the 48 interventions lacked
homogeneity, as did the collection of studies addressing breast cancer survivors.
[Insert Table 3 and Figure 2 here]
Factors Related to the Magnitude of CRF Modulation
Bivariate regression analyses examined potential sample, methodological, and
exercise intervention characteristics. Significant bivariate models were then integrated
into a combined moderator model to explain unique study variance (Table 4). When
integrated the following moderators no longer remained significant: session length (min),
number of exercise sessions, and treatment with radiation therapy. Four moderators
impacting CRF modulation in adult cancer survivors remained significant. Reductions in
CRF were greater to the extent interventions: (1) adhered to a theoretical model
(compared to those that did not do so) (β = 0.48, p = <.001); and (2) sampled older
cancer survivors (β = 0.24, p = .04). Also (3), the greatest reductions in CRF occurred
with moderate intensity (3-6 METs, 60-80%, 1-RM) resistance exercise (β = 0.60, p =
.01), particularly for higher quality interventions (interaction β = 0.23, p < .05).

In

contrast, lower quality interventions were efficacious in reducing CRF at low (<3 METs)
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and moderate intensity (3-6 METs, 60-80% 1-RM) resistance exercise. Intensity of
resistance exercise, use of theory, age, and methodological quality together explained
52% of the variance among exercise interventions for adult cancer survivors.

The

estimates in Table 4 reveal exercise interventions of moderate intensity (3-6 METs, 6080% 1-RM) resistance exercise were successful in reducing CRF, regardless of the use
of theory in the exercise intervention, age of the cancer survivor, and methodological
intervention quality.

In contrast, interventions of low intensity resistance (<3 METs,

<60% 1-RM) exercise showed no significant reduction of CRF when theory was absent
or in high methodological quality interventions. Time since diagnosis, aerobic exercise,
flexibility exercise, or supervision of exercise sessions did not moderate CRF
modulation.
[Insert Table 4 here]
Discussion
Overall, we found exercise moderately reduced CRF among cancer survivors
with an effect size of 0.31 (95% CI: 0.22, 0.40), consistent with prior reviews (12, 15). Of
note is our new finding that resistance exercise has a positive, quadratic, and exercise
intensity dose response effect on CRF. For cancer survivors engaging in moderate
intensity, resistance exercise (3-6 METs, 60-80% 1-RM) reduced CRF more so than
those engaging in lower intensity resistance or aerobic exercise of any level of physical
exertion. Another interesting finding was exercise interventions based upon a theoretical
model of behavior change or adaptation were more successful in reducing CRF than
those interventions not based upon such models.

Age was also related to CRF

reduction, with older cancer survivors reducing CRF to greater levels than younger
cancer survivors. Lastly, RCTs of stronger methodological quality (i.e., higher PEDro
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score) reduced CRF less than those of weaker methodological quality. Our findings
about

exercise

interventions

based

upon

theoretical

models

and

of

higher

methodological quality support previous meta-analytic work examining the influence of
exercise on CRF (11).

They also update the literature with a larger, more diverse

sample of cancer survivors and types of exercise interventions (11).
Sub-group analysis relating to cancer type revealed exercise moderately reduced
CRF, 0.39 (95% CI: 0.27, 0.51) and 0.42 (95% CI: 0.27, 0.57), among breast and
prostate cancer survivors, respectively. These findings update and support previous
meta-analytic reviews advocating the use of exercise as a non-pharmacological
intervention to reduce CRF among breast and prostate cancer survivors (11, 12). Subgroup analysis among leukemia, lymphoma, and colorectal cancer survivors yielded
non-significant reductions in CRF.
Four meta-analyses have been conducted examining the effect of exercise on
CRF (11-14).

Two of these meta-analysis have examined the mean reduction of

exercise on CRF (13, 14) without accounting for exercise characteristics that may
moderate the efficacy of exercise on CRF. The remaining two meta-analyses (11, 12)
have examined moderators relating to the efficacy of exercise in reducing CRF,
however, these meta-analyses were comprised of a smaller number of studies (i.e., 17
(11) and 18 studies (12)), and did not examine specific Ex Rx characteristics included in
our analysis that may impact CRF modulation. In our meta-analysis of 48 interventions,
we found exercise intensity was a significant moderator of CRF among adult cancer
survivors participating in resistance training programs.

A positive, quadratic pattern

emerged suggesting moderate intensity resistance exercise interventions were more
efficacious in diminishing CRF than those of lower intensity or aerobic exercise of any
Brown JC, et al. 2011. Cancer Epidemiology, Biomarkers & Prevention Jan 2011;20:123-133.
Copyright © 2010 American Association for Cancer Research
33

level of intensity. Our finding of the efficacy of resistance exercise reducing CRF was
somewhat unexpected. Current exercise guidelines for cancer survivors emphasize the
importance of participating in aerobic exercise, complimented with resistance and
flexibility exercises (ACSM Roundtable) (4) and often make no (National Comprehensive
Cancer Network) (3) or minimal mention (American Cancer Society) (17) of resistance
exercise.
A possible mechanism for the effectiveness of resistance exercise in reducing
CRF among breast and prostate cancer survivors is the attenuation of the progressive
muscle wasting and disruptions in muscle metabolism that occur with cancer and
associated treatments (85). Several hypotheses related to muscle protein synthesis,
adenosine triphosphate dysregulation, cytokine dysregulation and progressive muscle
wasting have all been postulated as mechanistic underpinnings of CRF (85, 86).
Moderate intensity resistance training increases muscle protein synthesis (87), improves
cytokine response (88), and diminishes the rate of sarcopenia (89) among healthy
human populations as well as those with compromised muscle function such as those
with cerebral palsy, and other musculoskeletal disorders (90). Further, recent evidence
suggests resistance exercise may provide health benefits such as improved total body
muscular strength, self-esteem, and vitality in breast and prostate cancer survivors (49,
72, 91).
Another interesting finding was older cancer survivors reduced CRF to greater
levels than younger cancer survivors engaging in any form of exercise. This finding is of
particular importance as most cancer survivors are older >65 yr (1), yet most exercise
interventions have focused on younger cancer survivors (4). Older cancer survivors are
frequently challenged with age-related declines in health (i.e., sarcopenia, decreased
Brown JC, et al. 2011. Cancer Epidemiology, Biomarkers & Prevention Jan 2011;20:123-133.
Copyright © 2010 American Association for Cancer Research
34

functional capacity) as well as cancer-related declines in health (e.g., cachexia, body
composition changes, decreased bone mineral density) (92). Exercise has been shown
to elicit favorable health outcomes among older prostate cancer survivors including,
increased lean body mass and muscle strength, and increase distance walked in 6
minutes (72). Improving the status of these health parameters (e.g., body-composition,
muscular strength, and cardiorespiratory fitness) may influence the modulation of CRF
among other populations of cancer survivors.
Exercise interventions that adhered to a theoretical model of behavior
change(86, 88) or adaptation model (82) achieved larger reductions in CRF than those
that did not adhere to such models. Theoretical models provide empirically supported
frameworks that inform behavior change, and may offer useful information about
determinants of exercise behavior (93, 94). An understanding of exercise behavior and
behavioral determinants among cancer survivors may help clinicians identify specific
intervention strategies to facilitation adoption and maintenance of an existing exercise
program in this population. Theoretical models of adaptation for cancer survivors may
be efficacious in improving psychological components of mental health (e.g., distress of
cancer diagnosis) potentially influencing CRF modulation. Despite the promise of such
interventions, relatively few of the studies implementing a theoretical framework
elaborated on the specific role of theory in the exercise intervention. Therefore, the
current meta-analysis is limited in its ability to determine the specific underpinnings of
theory mediating the reduction in CRF.
This study is subject to several limitations. Despite our comprehensive review of
the literature examining CRF in all types of cancer, our search yielded 28 of the 48
exercise interventions that targeted breast (58%) and prostate cancer (10%) survivors
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exclusively. The large number of interventions examining the impact of exercise on CRF
modulation among breast cancer survivors limits the generalizibility of our findings to
other types of cancer survivors. Moreover, we acknowledge that theories of behavior
change and adaptation models are hypothesized to influence fatigue through different
mechanisms. As noted, we combined them into a single category because there were
relatively few instantiations of theory-led interventions. Despite this limitation, the
efficacy of the application of either behavior change or adaptation models is promising
when compared to those not adhering to a pre-specified theory or model.
Another limitation relates to the major finding of this meta-analysis, that moderate
intensity resistance exercise may be beneficial in reducing CRF. In particular, no study
examined resistance exercise interventions >6 METs (>80% 1-RM). It remains unknown
if more vigorous intensity resistance training would provide greater or lesser reductions
in CRF. We did not evaluate adherence to the exercise interventions in this metaanalysis because most studies did not report this information. This variable should have
important moderating effects on CRF modulation.
In summary, we confirm with the largest meta-analysis of RCTs conducted to
date that moderate resistance exercise reduces CRF among adult cancer survivors,
particularly breast and prostate cancer survivors and those of older age.

Cancer

survivors engaging in moderate-intensity resistance exercise modulated CRF levels
more than those engaging in low-intensity resistance exercise or low to moderate
intensity, aerobic exercise. Further, the most efficacious exercise interventions were
based upon behavior change and adaptation theory. Our findings reinforce the notion
that exercise interventions for adult cancer survivors should be individualized based
upon the targeted health outcome and possibly cancer type.

In addition, exercise
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interventions should be multi-dimensional, combining sound exercise as well as
behavioral science.
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Figure 1. Flow diagram of trial identification and selection.
Potentially relevant RCTs
(k = 7,245)

RCTs Excluded (k = 7064)
1. No use of exercise (k = 4218)
2. Duplicates (k = 1301)
3. No Cancer survivors (k = 1297)
4. Targeted children (k = 248)

Retrieved RCTs
(k = 181)

RCTs Excluded (k = 94)
1. Not an RCT (k = 42)
2. No intervention (k = 27)
3. No use of exercise (k = 25)

Potentially appropriate RCTs
(k = 87)

RCTs Excluded (k = 43)
1. No use of exercise (k = 23)
2. Matching of groups (k = 17)
3. No measure of CRF (k = 3)

RCTs Included in final
analysis (k= 44)

Effect sizes calculated in final
analysis (k = 48)a

a

Four studies provided two interventions, yielding two effect size calculations

Brown JC, et al. 2011. Cancer Epidemiology, Biomarkers & Prevention Jan 2011;20:123-133.
Copyright © 2010 American Association for Cancer Research
39

Table 1. Descriptive characteristics of included studies. Means (±SD), except where
noted
Descriptive
Characteristic
All Cancer
Breast
Prostate
Lymphoma
Study Characteristics
Number of studies, k
44
25
4
4
Year of study
2005±3.5
2004±3.4
2006±2.7
2006±3.4
Use of theory
27%
22%
0%
0%
Published in journal
88%
84%
100%
100%
Subject Characteristics
Age
53.8±10.5
52.6±4.4
67.9±1.6
49.8±7.4
Type of treatment
Chemotherapy
13%
12%
0%
25%
Radiation
6%
8%
0%
0%
Hormones
6%
4%
80%
0%
Combination
75%
76%
20%
75%
Stage of treatment
Currently treated
46%
33%
80%
100%
Previously treated
54%
66%
20%
0%
Time since diagnosis, mo. 6.7±13.8
6.9±13.1
6.4±14.3
7.3±14.6
Intervention Characteristics
Intervention length, wk
11.5±5.2
11.8±4.4
16.0±7.5
12.3±8.3
Frequency, d/wk
3.5±1.4
3.4±1.1
2.6±0.4
3.3±1.7
Length, min/session
48.5±22.8
46.6±21.9
60.0±18.4
60.0±21.2
Aerobic Intensity, METs
5.6±3.0
4.9±2.1
4.9±5.2
5.6±3.5
Strength Intensity, METs
4.5±2.0
4.5±1.7
2.4±3.2
2.0±1.2
Flexibility
Included
52%
60%
40%
50%
Excluded
48%
40%
60%
50%
CRF scale used
FACT
30%
36%
60%
25%
Piper fatigue
20%
32%
0%
0%
POMS
13%
8%
0%
25%
Brief fatigue index
11%
4%
0%
0%
Linear analog scale
4%
4%
0%
0%
EORTC QOL-C30
11%
0%
20%
25%
Other
11%
16%
20%
25%
FACT, Functional assessment of cancer therapy. POMS, Profile of mood states.
EORTC QOL-C30, European organization for research treatment center quality of lifecare 30. METs, metabolic equivalent units. Percentages may not sum to 100% due
to rounding error.
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Table 2. Methodological quality of included studies by cancer type
Study quality dimension
3
+
+
-

4
+
+
+
+
+
+
+
+
+

5
-

6
+
-

7
+
-

8
+
+
+
+
+
+
+
+

9
+
+
+
+
+
+
+
+
+

10
+
+
+
+
+
+
+
+
+

11
+
+
+
+
+
+
+
+
+

Payne (44)
Galantino (45)
Segal (46)
Carson (47)
Mutrie (48)
Courneya (49)
Mock (50)
McKenzie (51)
Courneya (52)
Drouin (53)
Daley (54)
Yuen (55)
Courneya (56)
Pinto (57)
Pinto (58)
Mock (61)
Heim (60)
Mock (61)
Campbell (62)
Headley (63)
Milne (64)
Caldwell (65)
Vito (66)
Battaglini (67)
Barfoot (68)

Breast Cancer
5
+ +
4
+ +
7
+ +
7
+ +
10
+ + +
7
+ +
7
+ +
8
+ +
9
+ +
6
+ +
7
+ +
6
+ +
8
+ +
6
+ +
5
+ +
5
+ +
6
+ +
4
+ +
6
+ +
3
+ +
8
+ + +
7
+ +
7
+ +
8
+ +
7
+ +
-

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

-

+
+
-

+
+
+
+
-

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Segal (69)
Windsor (70)
Segal (71)
Galvao (72)

Prostate Cancer
6
+ +
6
+ +
10
+ + +
9
+ + +

+
+
+
+

-

+
-

+
+

+
+
+

+
+
+

+
+
+
+

+
+
+
+

Cohen (73)
Courneya (74)
Jarden (75)
Coleman (76)

9
7
7
5

+
-

+
+
+
+

-

-

-

+
+
+
-

+
+
+
+

+
+
+
+

+
+
+
-

-

+

-

-

+

+

+

+

+

Citation
Thorsen (35)
Brown (36)
Culos-Reed (37)
Dimeo (38)
Dimeo (39)
Adamsen (40)
Mustain (41)
Burnham (42)
Shang (43)

Courneya (77)

Total
7
7
7
6
7
10
8
7
7

1
+
+
+
+
+
+
+
+
+

2
+
+
+
+
+
+
+
+
+

Lymphoma
+ +
+ +
+ +
+ +
Colorectal
7
+ +

Leukemia
6
+ +
+
+
+
+
Chang (78)
1, eligibility criteria; 2, randomization; 3, concealed allocation; 4, baseline similarity of groups; 5,
subject blinding; 6, therapist blinding; 7, assessor blinding; 8, outcome measure from >85% of
subjects; 9, “intention to treat”; 10, between group statistical comparisons; 11, point & variability
measure.
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Figure 2. Forest plot of effect sizes gauging impact of exercise on CRF modulation by
cancer type with random-effects means.

Author

Citation

ES (95% CI)

Mixed Cancer Type
Thorsen
35
Brown
36
Culos-Reed
37
Dimeo
38
Dimeo
39
Adamsen
40
Mustian
41
Burnham
42
Shang
43
Subtotal (I-squared = 21.0%, p = 0.257)
.
Breast Cancer
Payne
44
Galantino
45
Segal (Supervised)
46
Segal (Unsupervised)
46
Carson
47
Mutrie
48
Courneya (Strength)
49
Courneya (Aerobic)
49
Mock
50
McKenzie
51
Courneya
52
Drouin
53
Daley
54
Yuen (Aerobic)
55
Yuen (Strength)
55
Courneya
56
Pinto
57
Pinto
58
Mock
59
Mock
60
Heim
61
Campbell
62
Headley
63
Milne
64
Caldwell
65
Vito
66
Battaglini
67
Barfoot
68
Subtotal (I-squared = 42.7%, p = 0.010)
.
Prostate Cancer
Segal (Strength)
69
Segal (Aerobic)
69
Windsor
70
Segal
71
Galvao
72
Subtotal (I-squared = 0.0%, p = 0.533)
.
Lymphoma
Cohen
73
Courneya
74
Jarden
75
Coleman
76
Subtotal (I-squared = 0.0%, p = 0.509)
.
Colorectal Cancer
Courneya
77
Subtotal (I-squared = .%, p = .)
.
Leukemia
Chang
78
Subtotal (I-squared = .%, p = .)
.
Overall (I-squared = 45.2%, p = 0.000)

-0.48 (-0.86, -0.10)
0.00 (-0.64, 0.64)
0.00 (-0.66, 0.66)
0.02 (-0.51, 0.54)
0.01 (-0.47, 0.49)
0.11 (-0.14, 0.37)
0.34 (-0.32, 1.00)
0.83 (-0.27, 1.92)
0.09 (-0.54, 0.72)
0.01 (-0.18, 0.20)
0.00 (-0.64, 0.64)
0.00 (-1.05, 1.05)
0.03 (-0.41, 0.46)
0.20 (-0.25, 0.64)
0.06 (-0.63, 0.75)
0.09 (-0.21, 0.39)
0.10 (-0.23, 0.42)
0.10 (-0.23, 0.42)
0.24 (-0.09, 0.57)
0.30 (-0.46, 1.07)
0.35 (-0.03, 0.74)
0.36 (0.07, 0.66)
0.42 (0.16, 0.68)
0.55 (-0.58, 1.68)
0.54 (-0.64, 1.72)
0.56 (-0.01, 1.13)
0.61 (-0.47, 1.68)
0.61 (0.17, 1.06)
0.70 (0.37, 1.03)
0.79 (-0.47, 2.05)
0.76 (0.47, 1.05)
0.84 (0.33, 1.36)
0.96 (0.52, 1.39)
1.12 (0.54, 1.70)
0.53 (-0.51, 1.58)
0.07 (-0.75, 0.89)
-0.13 (-1.06, 0.80)
0.12 (-0.81, 1.05)
0.39 (0.27, 0.51)
0.54 (0.09, 0.99)
0.29 (-0.15, 0.74)
0.32 (0.06, 0.57)
0.33 (-0.05, 0.71)
0.61 (0.32, 0.90)
0.42 (0.27, 0.57)
0.03 (-0.30, 0.35)
0.40 (0.04, 0.76)
0.25 (-0.41, 0.91)
0.05 (-1.74, 1.84)
0.20 (-0.03, 0.43)
0.06 (-0.38, 0.49)
0.06 (-0.38, 0.49)
0.78 (-0.14, 1.70)
0.78 (-0.14, 1.70)
0.31 (0.22, 0.40)

NOTE: Weights are from random effects analysis
-2

-1

-.5

Favors Control

0

.5

1

2

3

Favors Exercise
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Table 3. Weighted mean effect of exercise modulating CRF by type of cancer
d+ (95%CI)

Homogeneity of d's

Type of cancer k
Fixed-effects
Random-effects
Q
0.310
(0.217,
0.403)
All cancers
44*
0.312 (0.249, 0.375)
93.37
†
0.391
(0.268,
0.514)
25
Breast
0.388 (0.303, 0.472)
47.16
‡
0.420
(0.270,
0.570)
Prostate
4
0.420 (0.270, 0.570)
3.15
0.199
(-0.025,
0.425)
Lymphoma
4
0.199 (-0.025, 0.425)
2.32
…
Colorectal
1
0.057 (-0.469, 0.583)
…
…
Leukemia
1
0.779 (-0.141, 1.700)
…
Weighted mean effect size values (d+) are positive when the exercise intervention was
CRF compared to standard care. CRF, cancer-related fatigue. k, # of studies.
a
44 studies provided a total of 48 effect sizes.
b
25 studies provided a total of 28 effect sizes.
c
4 studies provided a total of 5 effect sizes.

P
I2 (95% CI)
50% (30, 64)
<.001
42% (10, 63)
<.001
0% (0, 96)
.533
0% (0, 99)
.508
…
…
…
…
successful in reducing
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Table 4. Intervention characteristics related to CRF reduction for all cancer survivors, showing estimates at light and
moderate levels of resistance exercise.
Estimates of d+ (95% CI)b
Intensity of Resistance Exercise
Study dimension
Levela
Light (2.0 METs)
Moderate (6.0 METs)
Use of theory
Absent
-0.034 (-0.207, 0.139)
0.361 (0.141, 0.582)
Present
0.354 (0.177, 0.531)
0.749 (0.470, 1.029)
Age
39 years
0.160 (0.009, 0.311)
0.555 (0.319, 0.791)
65 years
0.385 (0.205, 0.564)
0.780 (0.589, 0.971)
70 years
0.428 (0.214, 0.643)
0.823 (0.612, 1.035)
Intervention quality
Highest quality (PEDro=10)
0.010 (-0.197, 0.217)
0.594 (0.310, 0.879)
Mean quality (PEDro=6.8)
0.289 (0.165, 0.413)
0.684 (0.506, 0.862)
Lowest quality (PEDro=3)
0.631 (0.363, 0.900)
0.794 (0.339, 1.249)
NOTE: Weighted mean effect size values (d+) are positive when the exercise intervention was successful in reducing CRF
compared to standard care. CRF, cancer-related fatigue. METs, metabolic equivalent of task.
a
Levels represent values at the extreme observations of each moderator and for other values of interest within that range.
b
d+ and their 95% CI estimates statistically adjust for the presence of the moderators in the mixed-effects model, including the
linear and quadratic trends for strength intensity, use of theory, age, and intervention quality, held constant at their means
except for differences in strength intensity and the study dimension in question.
MET values were provided to demonstrate the emerging patterns among theory, age, and intervention quality with increasing
resistance exercise intensity, representing light (2.0 MET) and moderate (6.0 MET) intensity.
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Search strategy
Searches for studies concluded in February 2010 and utilized electronic
databases including CINAHL (1981 to 2010), MEDLINE (1949 to 2010), Embase (1973
to 2010), and Scopus (1996 to 2010). OregonPDF in Health and Performance (1947 to
2010), Proquest Dissertations, and Theses (1980 and 2010) were also searched for
unpublished literature including search words related to; 1) exercise, and 2) cancer and
3) fatigue. The following search strategy was utilized for this meta-analysis, using text
and keyword and MESH terms in each database, with and RCT filter applied:
The databases PubMed, PsycINFO, CINAHL Plus, SPORTSdiscus, OregonPDF in
Health and Performance, and ProQuest Theses and Dissertations were searched. We
searched all databases using a Boolean search strategy [i.e., (cancer OR neoplas* OR
tumor OR chemo* OR radiat* OR malign* OR carciniom*) AND (fatigue (fatig*) tired OR
lethargic OR vitality OR weary OR exhaust* OR energy OR apathy OR lassitude OR
weakness OR Drained OR sleepy OR sluggish) AND (exercise OR physical activity OR
aerobic OR cardiovascular OR resistance OR strength OR muscular OR flexibility OR
walking OR program OR interval OR sport OR fitness OR performance OR movement
OR stretching OR tai chi OR yoga OR dance OR body OR composition)]. Journals
focusing on cancer survivorship (Breast Cancer Research and Treatment, Journal of
Cancer Survivorship, Oncology Nursing Forum, Journal of Pain and Symptom
Management and the reference lists of included studies were also searched for
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additional papers and previous meta-analyses(12-14, 95) and systematic reviews (11,
13-15, 95-99) were searched for additional literature that database searches may have
missed.

Figure 3. Funnel plot of effect size estimates.
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Table 5. Characteristics of included studies (Online material only)
Subject Characteristics
Reference

Type of
Cancer
Lymphoma
Breast
Gynocologic

N
I=59

Thorsen (35)
Brown (36)

C=52
I=59

Mixed;
Not-Specified

C=58

Majority Breast;
Others Not
Specified
Breast
Lymphoma
Lung

I=20
Culos-Reed (37)

C=18
I=27

Dimeo (38)
Dimeo (39)

C=32
I=34

Lung
Intestinal

C=35

Exercise Characteristics

Type of Treatment

Frequency
(d∙wk-1)

Intensity

Time
(min∙d-1)

Duration
(wk)

CRF
Measure

Chemotherapy

2

60-70%
HRMax

30

14

EORTC-QOL
C30

Radiation

1

N/A

90

Yoga
Stretching

8

POMS

Not Specified

1

N/A

75

Yoga

7

POMS

Chemotherapy

7

30-50 RPM

30

BedErgometer

12

POMS

Chemotherapy
Radiation Surgery

5

80% HRMax

30

Stationary
Bike

3

EORTC-QOL
C30

90

Weights
Stationary
Biking

6

EORTC-QOL
C30

I=135
Adamsen (40)

Mustain (41)
Burnham (42)
Shang (43)

C=134
I=19
C=19
I=6
C=12
I=68
C=58

Type
Walking
Cyling
Jogging

21 Tumor
Types

Chemotherapy

3

85-90%
HRMax
70-100%
1RM

Breast Prostate

Chemotherapy

3

60-70% HR
Reserve

60

Walking
Stretch
Bands

4

BFI

Breast
Colon

Chemotherapy
Surgery

2

40-60%
HRMax

30

Treadmill
Biking

10

LAS

Breast Prostate
Colon

Chemotherapy
Radiaiton

4

50-70%
HRMax

30

Walking

13

PFS

Breast
Payne (44)
Galantino (45)

I=10
C=10
I=4
C=4

Breast

Hormone

4

Moderate
Intensity

20

Walking

12

PFS

Breast

Chemotherapy
Radiation

1

N/A

60

Tai Chi
Walking

3

BFI

3

50-60% V02
max
(Supervised)
30

Walking

26

SF-36

5

50-60% V02
max (SelfDirected)

I=42
Segal (46)

I=40
C=41

Breast

Chemotherapy
Radiation Surgery
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Carson (47)
Mutrie (48)

I=16
C=20
I=101
C=102

Breast

Chemotherapy
Surgery

1

N/A

120

Yoga

8

0-9 Scale

Breast

Chemotherapy
Radiation Surgery

3

50-75% HRmax

45

Walking
Cycling
Aerobics

12

FACT

45

CycleErgometer
Treadmill
Elliptical

17

FACT-A

70% V02 max

I=78
Courneya (49)

Breast

Chemotherapy

3
60-70% 1RM
2 Sets
8-12 Reps

45

WeightMachines

5

Moderate
Intensity

30

Walking

6

PFS

60

ArmErgometer
WeightMachines

8

SF-36

I=82
C=82
Mock (50)

McKenzie (51)

Courneya (52)
Drouin (53)
Daley (54)

I=60
C=59

I=7C=7

I=60
C=48
I=13
C=8
I=34
C=38

Breast

Chemotherapy
Radiation Surgery

Breast

Chemotherapy
Radiation Surgery

3

Ergometer:
25W
Two Sets
10 reps

Breast

Chemotherapy
Radiation

5

60-75 HRmax

30

Walking

10

FACT

Breast

Radiation

4

50-70% HRmax

45

Walking

8

PFS

Breast

Chemotherapy
Radiation Surgery

3

65-85% HRmax

50

NotSpecified

8

PFS

Breast

Chemotherapy
Radiation Surgery

3

12

PFS

Breast

Chemotherapy
Radiation

3

70-75% V02
max

45

CycleErgometer

15

FACT-B

Breast

Chemotherapy
Radiation Surgery

3

60-70% HRmax

50

AerobicActivities

12

POMS

Breast

Chemotherapy
Radiation Surgery

5

55-65% HRmax

30

Walking
Biking
Swimming

12

POMS

Breast

Chemotherapy
Radiation Surgery

5

Self-Paced

30

Walking

6

PFS

Breast

Chemotherapy
Radiation Surgery
Hormones

4

Not Specified

60

Walking
WeightMachines

12

FACT

I=7
Yuen (55)

I=8

Moderate

C=7
Courneya (56)
Pinto (57)
Pinto (58)
Mock (61)
Heim (60)

I=25
C=28
I=9
C=12
I=43
C=43
I=23
C=23
I=32
C=31

8-12 Reps
(circuit)

Walking
30

WeightMachines
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Mock (61)
Campbell (62)
Headley (63)

I=9
C=5
I=12
C=10
I=16
C=16

Breast

Chemotherapy
Radiation Surgery

3

Not Specified

30

Walking

16

SAS

Breast

Chemotherapy
Radiation

2

60-75% HRmax

45

Walking
Cycling
Aerobics

12

FACT-G

Breast

Chemotherapy

3

Moderate
Intensity

30

NotSpecified

16

FACT-F

Breast

Chemotherapy
Radiation Surgery

3

60

Cycling
Rowing
Weights

12

FACT-B

Breast

Chemotherapy
Surgery

4

30

Walking
ResistanceBands

12

SCFC
(Schwartz
Cancer)

Breast

Chemotherapy
Radiation

2

90

Yoga

8

FACT-B

Breast

Radiation

2

60

Treadmill
Cycling
Weights

15

PFS

Breast

Chemotherapy
Radiation

2

60

CycleErgometer
Weights

14

PFS

24

FACT-F

I=29
Milne (64)

C=29
I=13

Caldwell (65)
Vito (66)

C=12
I=13
C=12
I=10

Battaglini (67)

Barfoot (68)

C=10
I=10
C=10

Moderate
Intensity
2 sets
10-15 reps
Light Intensity
Light
Resistance
N/A
Moderate
Intensity
3 Sets
8-12 Reps
40-60% HRmax
2-3 Sets
6-12 Reps

Prostate
70-75% V02
max

I=40
Segal (69)

I=40

Prostate

Radiation

3

C=41
Windsor (70)
Segal (71)
Galvao(72)

I=33
C=33
I=82
C=73
I=29
C=29

Cycling

60-70% 1RM
2 sets 8-12
reps

45
Weights

Prostate

Radiation
Hormones

3

60-70% HRmax

30

Walking

8

BFI

Prostate

Hormones

3

2 sets
8-12 reps

60

Weights

12

FACT-F

Prostate

Transplant

2

2-4 sets
6-12 reps

45

Weights

12

EORTC-QOL
C30

Lymphoma
Cohen (73)
Courneya (74)
Jarden (75)

I=20
C=19
I=60
C=62
I=21

Lymphoma

Chemotherapy
Radiation

1

N/A

60

Yoga

7

BFI

Lymphoma

Chemotherapy
Radiation

3

75% V02 max

45

CycleErgometer

12

FACT-A

Lymphoma

Chemotherapy

5

50-75% HRmax

30

Cycle

5

EORTC-QOL
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C=21

Transplant

C30

N/A

20

Walking
Cycling
Stretch
Bands

65-75% HRmax

30

Walking

16

FACT-C

Moderate

12

Walking

3

BFI

I=14
Coleman (76)

C=10

Multiple
Myleoma

Chemotherapy

3

24

POMS

Colorectal
I=69
Courneya (77)

C=33

Colorectal

Chemotherapy
Surgery

4
Leukemia

Chang (78)

I=11
C=11

Leukemia

Chemotherapy

5

Wk: week; min: minutes; HRmax : Maximum Heart Rate; HRR: Heart Rate Reserve; V02 max: maximum oxygen consumption; reps: repetition. FACT: Functional Assessment
of Cancer Therapy; BFI: Brief Fatigue Index; POMS: Profile of Mood States; EORTC-QOL C-30: Quality of Life Compact 30; PFS: Piper Fatigue Scale; LAS/SAS:
Linear/Symptom Analog Scale. I = n for intervention group; C = n for control group
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Abstract
Introduction:

The purpose of this meta-analysis was to examine the efficacy of

exercise in reducing depression among cancer survivors. In addition, we examined the
extent to which exercise dose and clinical characteristics of cancer survivors influenced
the relationship between exercise and reductions in depression.
Methods: We conducted a systematic search identifying randomized controlled trials of
exercise interventions among adult cancer survivors examining depression as an
outcome. We calculated effect sizes for each study and performed weighted multiple
regression moderator analysis.
Results:

We identified 40 exercise interventions including 2,929 cancer survivors.

Diverse groups of cancer survivors were examined in seven exercise interventions;
breast cancer survivors were examined in 26; prostate cancer, leukemia, and lymphoma
were examined in two; and colorectal cancer in one. Cancer survivors who completed
an exercise intervention reduced depression more than controls, d+=-0.13 (95% CI: 0.26, -0.01). Aerobic exercise reduced depression in dose response fashion (β=-0.24,
p=0.03), a relationship evident in higher quality trials. Depression was reduced most
when exercise sessions were supervised (β=0.26, p=0.01); and cancer survivors were
between the ages of 47–62 yr (β=0.27, p=0.01).
Conclusion: Exercise training provides a small overall reduction in depression among
cancer survivors but one that increased in dose-response fashion with aerobic exercise.
Depression was reduced to the greatest degree among breast cancer survivors, among
cancer survivors aged between 47–62 yr, or when exercise sessions were supervised.
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Introduction
There are over 12 million cancer survivors in the US (1). Nearly 100% of all
cancer survivors experience psychological and physical symptoms and side effects
related to cancer or cancer treatment (2). Cancer survivors may experience fear of
death, disease relapse, and body image changes (3) that may contribute to the
depression experienced by up to 60% of cancer survivors (4) compared to 7% of the
general US population (5). Depression associates with chemotherapy noncompliance
(6, 7) and reduced 5 yr survival rates (8, 9). Therefore, management of depression
among cancer survivors is of clinical importance. Exercise is an effective nonpharmacological therapy to reduce depression among healthy populations (10) with a
moderate standardized mean reduction when compared to those who do not exercise.
Exercise provides similar or larger reductions in depression among an array of clinical
populations including those living with chronic obstructive pulmonary disease (11),
human immunodeficiency virus (12), and coronary artery disease (13).
Accumulating evidence suggests exercise training after diagnosis of cancer may
reduce the symptoms associated with cancer survivorship, improve quality of life and
reduce cancer-related fatigue (14, 15). However, the efficacy of exercise to reduce
depression is inconclusive (2). Some studies have demonstrated moderate to large
reductions in depression as the result of exercise programs (16, 17), whereas others
observe no such reductions (18, 19). Although a previous meta-analysis (20) quantified
the heterogeneity of exercise interventions to reduce depression among cancer
survivors and reported a moderate to large amount of heterogeneity (I2=55%–76%), it
did not examine moderator variables that could explain the heterogeneity in results.
Therefore, this meta-analysis examined the efficacy of exercise to reduce
depression among cancer survivors and attempted to identify exercise prescription and
clinical factors associated with the greatest reductions in depression. Identification of
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characteristics moderating the magnitude of reduction in depression may aid clinicians in
prescribing tailored exercise interventions to better manage depression among cancer
survivors.
Methods
Inclusion Criteria
Studies were included if they: (1) utilized a randomized controlled design
comparing an exercise intervention with a control group (i.e., no exercise program
prescribed and instructions to maintain current activity levels or no exercise related
information); (2) reported depression outcomes; and (3) targeted adults diagnosed with
any type of cancer, regardless of stage of diagnosis or type or stage of treatment.
Exercise interventions occurring in any setting, with or without supervision, were eligible.
Systematic Search [See supplementary material for systematic search strategy]
Coding and Reliability
Four independent, trained raters extracted information related to the study with
high inter-rater reliability, mean Cohen’s

=0.90, for categorical variables, and mean

intra-class correlation r=0.94 for continuous variables. Absolute intensity of exercise
was coded using metabolic equivalent units (METs), where 1 MET represents sitting
quietly (3.5 ml O2∙kg-1∙min-1) and <3 METs, 3 to <6 METs, and ≥6 METs represent low,
moderate, and vigorous intensity exercise, respectively (21). We calculated the weekly
volume of aerobic exercise as the product of minutes of daily exercise and frequency of
exercise sessions per week (min∙wk-1). The Physiotherapy Evidence Database scale
(PEDro) assessed methodological quality of the trials in terms of internal validity and
statistical reporting (22).
Study Outcome and Effect Size Calculation
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Assessment of depression levels among cancer survivors was a continuous
outcome variable assessed as a component of a comprehensive psychological
questionnaire with a depression subscale (23) or a questionnaire solely assessing
depression levels (24-27) (Table 1). In order to standardize these differences across
studies, the standardized mean difference effect size (d) was calculated to determine the
difference in depression at follow-up between the exercise and control groups, correcting
for small sample size bias and baseline depression levels (28, 29).

For two group

comparisons, d denotes the difference between the mean depression values of the
control and exercise groups, divided by the pooled standard deviation (30). When more
than one exercise group was provided (e.g., aerobic exercise and resistance exercise)
we calculated multiple effect sizes.

Subsequent sensitivity analysis examined the

dependence between these effect sizes to confirm the weighted mean effect size of all
exercise trials (d+) was not influenced by an individual effect size (31). A negative d
value indicated the exercise was efficacious in reducing depression compared to the
control group.
Stata 11.1 (StataCorp, College Station, TX) with macros developed for metaanalysis (32) performed all statistical analyses.

Prior to analysis, Begg’s test (33)

(z=-1.67, p=0.10), Egger’s test (34) (t=-0.12, p=0.90), and the trim-and-fill method (35)
identified no asymmetries in the effect size distribution suggestive of publication bias.
Potential heterogeneity or between-study variance was calculated as Q and I2 (and 95%
CI) (36, 37). I2 ranges from 0% to 100% with low values suggesting homogeneity and
large values signifying heterogeneity. To explain variance in the effect size estimates—
the relation between study level characteristics and the magnitude of effect size—a
modified, weighted least squares regression was used with weights equal to the inverse
variance of each exercise intervention effect size (viz., meta-regression). All statistical
models pursued fixed effects assumptions. Statistically significant bivariate regression
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analyses were integrated into a multi-moderator fixed effects regression to determine
which variables could be eliminated and which explain unique between study variance.
To reduce multicollinearity in multiple meta-regression models, all continuous variables
were zero centered, and categorical variables were contrast coded (-1/+1). Two-sided
statistical significance was p<0.05.
Results
Methodological Characteristics
Qualifying were 37 relevant randomized controlled exercise interventions (16-19,
38-70) (N=2,929) with a total of 40 comparisons (k=40) of exercise versus control
conditions (Figure 1; Supplementary material describes each trial). Thirty-four studies
provided one effect size, and three provided two effect sizes (19, 40, 48). The mean
publication year of the exercise interventions was 2006±4.2. A majority of studies (70%)
were conducted in North America. The mean PEDro score of the exercise interventions
was 7.0±1.0 indicating high quality (22). Implementation of a theory of behavior change
occurred in 20% of the exercise interventions (Table 1).

Questionnaires assessing

depression included the Center for Epidemiologic Studies-Depression (25) (40%), Profile
of Mood States (23) (23%), Beck Depression Inventory (24) (18%), Hospital Anxiety and
Depression Scale (26) (12%), and Symptom Assessment Scale (27) (7%).
[Insert Table 1 & Figure 1 here]
Cancer Survivor Characteristics
Cancer survivors participating in the exercise trials averaged 51.3±6.5 yr (range:
39–70). The majority of cancer survivors participating in the exercise interventions were
white, non-Hispanic (n=2,255; 77%) women (n=2,548; 87%).

Time since cancer

diagnosis was 25.3±19.6 months (range: 2.8–73.0). Exercise interventions were more
common during curative therapy with 29 of the 40 exercise interventions (73%) occurring
during treatment (i.e., chemotherapy or radiation treatment). Diverse groups of cancer
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survivors were examined in six exercise interventions (38-43), while breast cancer
survivors were examined in 24 (16, 19, 44-65); prostate cancer (18, 66), leukemia (68,
69), and lymphoma (17, 70) in two; and colorectal cancer survivors in one (67).
Exercise Intervention Characteristics
The mean length of the 40 exercise interventions was 13.2±11.7 wk with a
session frequency of 3.0±2.5 d∙wk-1 for 49.1±27.1 min∙session-1.

Average weekly

volume of all exercise was 129.4±64.9 min∙wk-1. Exercise modalities included walking
(k=16; 40%), stationary cycling (k=5; 13%), weight machines (k=2; 5%), resistance
bands (k=3; 8%), and yoga (k=8; 20%). In addition, flexibility exercises were prescribed
in 50% of the exercise interventions. The absolute intensity of exercise was 3.9±1.3
METs indicating they were of low (i.e., <3 METs) to moderate (i.e., >3 to <6 METs)
intensity. A majority of exercise interventions (60%) were supervised.
The Influence of Exercise on Depression
Exercise provided a small overall reduction in depression compared to standard
care among all types of cancer [d=-0.13 (95% CI: -0.26, -0.01)]. Subgroup analysis by
cancer type revealed significant reductions in depression among breast cancer survivors
[d=-0.17 (95% CI: -0.32, -0.02)], but no significant difference in depression among
prostate, leukemia, lymphoma, and colorectal cancer survivors (Table 2). Collectively,
the 40 effect sizes of the exercise interventions lacked homogeneity [I2=55% (95% CI:
35–68), p<0.001], as did the analysis restricted to breast cancer survivors [I2=59% (95%
CI: 37‒73), p<0.001; Table 2].
[Insert Table 2 here]
Moderators of the Influence of Exercise on Depression
Three moderators explained unique variance relating to the efficacy of exercise
to reduce depression when entered in a multiple regression model. Weekly volume of
aerobic exercise reduced depression in dose response fashion (β=-0.24, p=0.03), a
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pattern that was more evident in higher quality trials. Depression was reduced most
when exercise sessions were supervised (β=0.26, p=0.01); and cancer survivors were
between 47–62 yr [(β=0.27, p=0.01); Table 3]. The following bivariate moderators
ceased being statistically significant in the face of the former variables: (1) theory; (2)
proportion of cancer survivors being non-Hispanic, white race; and (3) months since
cancer diagnosis (Table 5, supplementary).
[Insert Table 3 here]
Discussion
This review found that exercise provided a small overall reduction in depression
among cancer survivors, d=-0.13 (95% CI: -0.26, -0.01), but the amount of change
varied widely across studies. We also attempted to elucidate the exercise dose and
clinical characteristics modulating the overall reduction of depression among cancer
survivors.

The new and intriguing findings from these moderator analyses were

depression reductions were influenced by age, supervision of exercise, and weekly
volume of aerobic exercise. The largest reductions appeared among cancer survivors
between 47–62 yr, when exercise was supervised, or as weekly volume of aerobic
exercise increased. These trends retained significance in a model that included all
factors simultaneously, suggesting each term has a unique impact in influencing
depression levels.
Our analysis revealed exercise reduced depression among breast cancer
survivors, d=-0.17 (95% CI: -0.32, -0.02), a pattern that confirms previous reports in the
literature (71). We observed non-significant reductions in depression among prostate,
colorectal, leukemia, and lymphoma survivors, but the lack of statistical significance
among these types may be due in part to the small numbers of included studies and
subsequent lowered statistical power to detect differences.

66

Depression reduction occurred in dose response fashion with aerobic exercise
such that as weekly minutes of aerobic exercise increased so did reductions in
depression, a finding observed in higher quality trials (Table 3). These trends are
consistent with experimental evidence suggesting exercise reduces depression in dose
response fashion among otherwise healthy populations (72).

Consistent with our

findings, the American College of Sports Medicine consensus statement in exercise and
cancer survivorship suggests all cancer survivors strive to achieve a large volume of
aerobic exercise of ≥150 min∙wk-1 to maximize the health benefits (2). However, the
clinical translation of advocating larger doses of weekly aerobic exercise may be an
unrealistic initial exercise prescription for some cancer survivors for many reasons (e.g.,
previous sedentary behavior, constraints of the disease process itself, other comorbities)
as well as more traditional barriers to exercise such as lack of time (73, 74).
Accumulating large volumes of aerobic exercise should be progressive, increasing
duration and frequency of exercise over weeks or months of exercise training as the
course of the disease process allows and fitness increases (73, 75).
We found supervised exercise reduced depression more so than unsupervised
exercise; consistent with improvements in quality of life (14) and fatigue reduction (76)
among cancer survivors, and reducing depression among apparently healthy
populations (77). Supervised exercise training is preferred over unsupervised exercise
by breast and colon cancer survivors (78, 79), and provides opportunity to receive
positive feedback and support, increasing compliance and associated mental and
physical health benefits (80).
We found cancer survivors between the ages of 47–62 yr reduced depression
more than <47 and >62 yr, respectively.

The quadratic shape was unexpected as

previous reports suggest a negative correlation between depression and age among
cancer survivors (81, 82).

Therefore, we hypothesized it would be younger cancer
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survivors experiencing the greatest reductions in depression occurring in linear fashion.
It is unclear why cancer survivors <47 yr did not experience exercise-induced reductions
in depression. It is plausible the average weekly aerobic exercise volume performed
(~130 min·wk-1) was not a large enough dose of exercise to reduce depression among
cancer survivors <47 yr.

Functional capacity (i.e., V02peak) and age are negatively

correlated (83). Thus, reducing depression among cancer survivors <47 yr may require
a larger volume of aerobic exercise to elicit reductions in depression. Conversely, the
lack of detecting a significant reduction in depression among cancer survivors >62 yr
may be due in part to a floor effect (10).

That is, older cancer experience less

depression at baseline, and show smaller exercise-induced improvements in depression
compared to those who are younger (84).
The findings from this meta-analysis provide additional insight to the physiology
of depression. The therapeutic efficacy of monoamine oxidase inhibitors and tricyclic
anti-depressant medications support the hypothesis of monoamine dysregulation as a
mechanistic underpinning of depression (85).

Anti-depressants act to increase

circulating monoamines (86) and similar increases occur in response to acute and
chronic aerobic exercise (87).

Acute aerobic exercise increases noradrenaline,

adrenaline, and serotonin above pre exercise levels (87, 88). Chronic aerobic exercise
training increases noradrenaline, adrenaline, and serotonin levels above the levels
elicited by an acute bout of aerobic exercise (87, 89). The higher concentrations of
monoamines elicited in response to chronic aerobic exercise training support the use of
chronic aerobic exercise training to reduce and manage depression (77). This supports
our findings that accumulating larger weekly volumes of repeated bouts of aerobic
exercise reduce depression in dose response fashion among cancer survivors.
However, the monoamine hypothesis is one hypothesis of the etiology of depression.
Continued research should investigate the complex physiology of depression and
68

exercise.

In particular, identification of biomarker responses occurring with varying

doses of aerobic exercise and their subsequent influence on depression.
Limitations
Despite our intention to include all types of cancer of any race, 26 of the 40 effect
sizes (65%) targeted white, non-Hispanic, breast cancer survivors exclusively which has
been a limitation of previous meta-analyses examining a variety of health-related
outcomes among cancer survivors (14, 15, 20).

The skewed number of exercise

interventions among breast cancer survivors limits the generalizability of our findings to
other types of cancer. This limitation should provide an impetus for researchers to
continue investigating the effects of exercise among other cancer types.
Despite an overall rating of high methodological quality (7.0±1.0 of 11), we did
note some consistent methodological weaknesses throughout the literature, such as
inclusion of small sample sizes, inconsistent criterion with respect to study entry
eligibility and baseline depression levels, and not following intent-to-treat analytic
strategies.
Conclusion
In closing, we confirmed that exercise provides a small reduction in depression
among cancer survivors, particularly among breast cancer survivors.

Depression

reduction occurred in dose response fashion with aerobic exercise. Larger reductions in
depression also occurred with supervised exercise, and among cancer survivors 47–62
yr. Cancer survivors should strive to avoid inactivity; discuss the safety and feasibility of
exercising with their medical care provider to optimize physical and psychological
symptom management and improvement; and eventually aim to achieve larger weekly
volumes of aerobic exercise of aerobic exercise if possible (2).
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Table 1. Descriptive characteristics of included studies, subjects and exercise interventions by type of cancer (means ± SD, k
or % where noted)
Descriptive Statistic
All Cancer
Breast
Prostate
Leukemia
Lymphoma
Study Characteristics
Number of studies, k
40a
26b
2
2
2
Year of study
2006±4.2
2006±3.9
2008±2.1
2008±0.7
2006±3.5
Published in journal, k
34
21
2
2
2
PEDro quality
7.0±1.0
6.7±1.1
7.0±0.0
7.5±0.7
7.5±0.7
Subject Characteristics
Total n (% total n)
2929 (100)
1796 (61)
121 (4)
66 (2)
161 (6)
Gender, n of women (%
2548 (87)
1796 (100)
121 (0)
22 (33)
61 (38)
total n)
Ethnicity, n (% total n)
White, non-Hispanic
2255 (77)
1437 (80)
–
–
–
African-American
498 (17)
296 (16)
–
–
–
Hispanic
88 (3)
54 (3)
–
–
–
Asian
59 (2)
18 (1)
–
–
–
Age, yr
51.3±6.5
50.9±4.7
68.5±1.2
45.2±8.6
52.1±1.5
Stage of treatment, k
Currently treated
29
17
2
2
2
Previously treated
11
9
0
0
0
Time since diagnosis, mo
25.3±19.6
26.9±21.3
–
–
29.2±8.0
Exercise Intervention Characteristics
Intervention length, wk
13.2±11.7
15.5±14.2
12.0±5.6
4.0±1.4
9.5±3.5
Length, min∙session-1
49.1±27.1
54.7±27.5
65.0±35.4
36.0±33.9
61.2±40.6
Frequency, session∙wk-1
3.0±2.5
2.8±1.3
2.0±1.4
5.0±0.0
2.0±1.4
-1
Exercise volume, min∙wk
123.9±52.2
135.2±25.1
105.0±21.2
180.0±169.7
97.5±0.0
Aerobic intensity, MET
4.8±1.1
4.7±0.9
4.4±0.8
5.4±2.3
7.0±0.0
Strength intensity, MET
2.9±0.5
2.9±0.6
3.0±0.0
3.0±0.0
2.5±0.0
Neuromuscular, MET
2.5±0.0
2.5±0.0
–
–
2.5±0.0
Flexibility, k
Included
20
13
2
1
1
Excluded
20
13
0
1
1
Supervision, k
Supervised
24
19
2
2
2
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Unsupervised
16
7
–
–
–
Use of theory, k
None
32
21
2
2
1
Psychological
8
5
0
0
1
Depression Scale used, k
CES-D
16
9
1
–
2
POMS
9
7
–
1
–
BDI
7
6
1
–
–
HADS
5
2
–
1
–
SAS
3
2
–
–
–
NOTE: Percentages may not sum to 100% due to rounding error.
CES-D, Center for Epidemiologic Studies Depression scale; POMS, Profile Of Mood States; BDI, Beck Depression Inventory;
HADS, Hospital Anxiety and Depression Scale; SAS, Symptom Assessment Scale.
k, number of studies included.
MET, metabolic equivalent, 1MET = 3.5 ml O2∙kg∙min-1.
a
37 studies provided 40 total effect size estimates
b
24 studies provided 26 total effect size estimates.
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Table 2. Weighted mean effect of exercise modulating depression by type of cancer
d+ (95% CI)
Homogeneity of ds
Type of Cancer k
Fixed-Effects
Random-Effects
I2 (95% CI)
Q
P
a
All Cancer
40
-0.13 (-0.21, -0.06)
-0.13 (-0.26, -0.01)
86.13
55% (35, 68)
<0.001
Breast
26b
-0.19 (-0.28, -0.09)
-0.17 (-0.32, -0.02)
60.79
59% (37, 73)
<0.001
Prostate
2
-0.20 (-0.66, 0.25)
-0.20 (-0.82, 0.40)
0.00
0% (0, 100)
0.948
Leukemia
2
-0.22 (-0.73, 0.30)
-0.24 (-0.89, 0.40)
0.94
0% (0, 100)
0.332
Lymphoma
2
-0.35 (-0.67, -0.03)
-0.30 (-0.89, 0.29)
0.64
0% (0, 100)
0.424
Colorectal
1
-0.08 (-0.52, 0.35)
–
–
–
–
NOTE: Weighted mean effect size values (d+) are negative when the exercise intervention was successful in reducing
depression compare to standard care.
k, number of studies.
a
37 studies provided 40 total effect size estimates.
b
24 studies provided 26 total effect size estimates.
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Table 3. Multi-moderator intervention characteristics related to depression change for all cancer survivors
Study dimension and levela
Adjustedb d+ (95% CI)
βc
-1
Accumulated weekly
PEDro=5 (lower
90 min∙wk
-0.29 (-0.54, 0.04)
-0.24d
volume of aerobic
quality)
120 min∙wk-1
-0.19 (-0.40, 0.02)
1
150 min∙wk-1
-0.09 (-0.34, 0.14)
exercise, min∙wk
-1
180
min∙wk
0.00 (-0.34, 0.34)
PEDro methodological
-1
PEDro=10 (higher
90 min∙wk
-0.07 (-0.42, 0.27)
score
quality)
120 min∙wk-1
-0.28 (-0.54, -0.02)
-1
150 min∙wk
-0.49 (-0.77, -0.23)
-1
180 min∙wk
-0.71 (-1.09, -0.33)
Supervision of exercise
Unsupervised
-0.13 (-0.23, -0.04)
0.26
Supervised
-0.36 (-0.55, -0.18)
Age,e y (Quadratic)
40
0.16 (-0.08, 0.41)
0.27
50
-0.20 (-0.30, -0.10)
60
-0.25 (-0.42, -0.08)
70
0.01 (-0.47, 0.56)
NOTE: Weighted mean effect size values (d+) are negative when the exercise intervention
reduced depression compared to the control group. The regression equation is -0.2289–
0.0164(age, y)+0.0016(age2, y)+0.1117(supervised)–0.0993(PEDro)–0.0007(Min week aerobic
exercise)–0.0021(PEDro×Min week aerobic exercise), where each continuous variable was zerocentered, and categorical variables were contrast coded (+1 vs -1).
a
Levels represent values of interest of each moderator.
b
d+ and their 95% CI estimates statistically adjust for the presence of the rest of the moderators in the
fixed-effects model, including weekly minutes of exercise PEDro interaction and their independent
linear terms, supervision of exercise, quadratic and linear trends for age, held constant at their means
except for the study dimension in question.
c
β values are standardized.
d
β for interaction. Independent β: weekly aerobic volume, β = -0.09; PEDro methodological score, β = -0.28.
e
Continuous quadratic trend including linear component.
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P
0.03

0.01
0.01

Figure 1. Flow diagram of exercise intervention identification and selection
Relevant Abstracts
(k=14702)

Abstracts Excluded (k=14594)
1. Duplicates (k=4407)
2. No cancer survivors (k=4632)
2. No exercise (k=3859)
4. Targeted children (k=1696)

Potentially Relevant Sources
(k=108)

Studies Excluded (k=37)
1. Not an RCT (k=18)
2. No use of exercise (k=11)
3. No intervention (k=8)

Potentially Appropriate RCTs
(k=71)

RCTs Excluded (k=34)
1. Matching of groups (k=28)
2. No use of exercise (k=4)
3. No measure of depression (k=2)

RCTs Included in Final
Analysis (k=37)

Effect Sizes Calculated in
Final Analysis (k=40)a

a

Three studies provided two interventions, yielding two effect size calculations
RCT, Randomized controlled trial
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Table and Figure titles and footnotes:
Table 2. Descriptive characteristics of included studies, subjects and exercise
interventions by type of cancer (means ± SD, k or % where noted)
NOTE: Percentages may not sum to 100% due to rounding error.
CES-D, Center for Epidemiologic Studies Depression scale; POMS, Profile Of Mood
States; BDI, Beck Depression Inventory; HADS, Hospital Anxiety and Depression Scale;
SAS, Symptom Assessment Scale.
k, number of studies included.
MET, metabolic equivalent, 1MET = 3.5 ml O2∙kg∙min-1.
a

37 studies provided 40 total effect size estimates

b

24 studies provided 26 total effect size estimates.

Table 2. Weighted mean effect of exercise modulating depression by type of cancer

NOTE: Weighted mean effect size values (d+) are negative when the exercise
intervention was successful in reducing
depression compare to standard care.
k, number of studies.
a

37 studies provided 40 total effect size estimates.

b

24 studies provided 26 total effect size estimates.

Table 3. Multi-moderator intervention characteristics related to depression change for
all cancer survivors
NOTE: Weighted mean effect size values (d+) are negative when the exercise
intervention reduced depression compared to the control group. The regression
equation is -0.2289 – 0.0164(age, yr) + 0.0016(age2, y) + 0.1117(supervised) –
0.0993(PEDro) – 0.0007(Min week aerobic exercise) – 0.0021(PEDro × Min week
aerobic exercise), where each continuous variable was zero-centered, and
categorical variables were contrast coded (+1 vs -1).
a

Levels represent values of interest of each moderator.

b

d+ and their 95% CI estimates statistically adjust for the presence

of the rest of the moderators in the fixed-effects model, including
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weekly minutes of exercise

PEDro interaction and their

independent linear terms, supervision of exercise, quadratic and
linear trends for age, held constant at their means except for the
study dimension in question.
β values are standardized.

c

β for interaction. Independent β: weekly aerobic volume, β = -0.09; PEDro

d

methodological score, β = -0.28.
e

Quadratic trend including linear component.

Figure 1. Flow diagram of exercise intervention identification and selection
FOOTNOTE: a Three studies provided two interventions, yielding two effect size
calculations
RCT, Randomized controlled trial
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Systematic search strategy (Supplementary).
The databases PubMed, PsycINFO, CINAHL Plus, SPORTSdiscus, OregonPDF
in Health and Performance, and ProQuest Theses and Dissertations were searched
through Nov 18, 2010. We searched all databases using a Boolean search strategy [i.e.,
(cancer OR neoplas* OR tumor OR chemo* OR radiat* OR malign* OR carciniom*) AND
(depress* OR anxiety OR anxious OR worried OR scared OR nervous OR cognitive OR
biofeedback OR relaxation OR social support OR mind-body) AND (exercise OR
physical activity OR aerobic OR cardiovascular OR resistance OR strength OR muscular
OR flexibility OR walking OR program OR interval OR sport OR fitness OR performance
OR movement OR stretching OR tai chi OR yoga OR dance OR body OR composition)].
Journals focusing on cancer survivorship (Breast Cancer Research and Treatment,
Journal of Cancer Survivorship, Oncology Nursing Forum, Journal of Pain and Symptom
Management and the reference lists of included studies were also searched for
additional

papers.
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Table 4. Clinical, exercise and methodological characteristics of included studies. Supplementary.
Clinical Characteristics
Exercise Characteristics
First Author,
Year,
Type of
Freq
Time (min∙
Sample Size
Intensity
-1
-1
Reference
Cancer
(d∙wk )
session )
Mixed Cancer Diagnoses
Burnham,
2002,(38)

I = 12
C=6

Breast
colon

3

40‒60% HRR

30

Dimeo,
1999,(39)

I = 27
C=32

Variety; solid
tumors,
lymphoma

7

50% HRR

30

Dodd,
2010,(40)

I = 44
I (Delayed) =
36
C = 39

Breast
Colorectal
Ovarian

3‒5

60‒80%
V02peak

20‒30

Berglund,
1994,(41)

I = 98
C = 101

2

n/a

60

Courneya,
2003,(42)

I = 60
C = 48

3‒5

65‒75%
HRmax

Thorsen,
2005,(43)

I = 59
C = 52

2

60‒70%
HRmax

Majority
Breast
cancer
Breast
Colon
Ovarian
Stomach
Melanoma
Hodgkin
NonHodgkin’s
Brain
Lung
Lymphoma
Breast
Gynecologic
Testicular

Type
Aerobic;
treadmill,
stationary
cycle, stair
climber
Aerobic;
supine biking
ergometer
Aerobic;
walking,
jogging,
bicycling

Duration
(wk)

Methodological Characteristics
Depression
PEDro Score
Measure

10

LASA

7

4

POMS

8

52

CES-D

8

n/a

7

HADS

7

20‒30

Aerobic;
swimming,
cycling

10

CES-D

8

30

Aerobic;
walking,
cycling,
jogging

14

HADS

8

50

n/a

8

BDI

8

15‒45

Aerobic: cycle
ergometer,
treadmill,
elliptical
9 strength

17

CES-D

7

Breast Cancer
Daley,
2007,(16)

I = 34
C = 36

Courneya,
2007,(19)

I (Aer) = 78
I (RET) = 82
C = 82

Breast

Breast

3

65‒85%
HRmax

3

60‒70%
V02max
2 Sets,
60‒70%
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First Author,
Year,
Reference

Culos-Reed,
2006,(44)
Rausch,
2007,(45)
Ohira,
2006,(46)

Perna,
2010,(47)

Clinical Characteristics
Type of
Sample Size
Cancer

I = 20
C = 18
I = 15
C=8
I = 43
C = 43

I = 26
C = 25

Exercise Characteristics
Freq
Intensity
-1
(d∙wk )
predicted 1RM

Time (min∙
-1
session )

I = 16
C = 18

Majority
breast

1

n/a

75

Yoga

7

POMS

7

Breast

1

n/a

90

Tai Chi

10

POMS

5

Breast

2

60

Weight
training

24

CES-D

6

12

CES-D

9

8

BDI

5

Breast

Progressive
resistance
Aerobic:
50‒85%
HRmax

Aerobic;
treadmill
walking
30

3

Breast

1

Weight
training;
weight belts

Light (<40%
1-RM), elastic
band,
medicine ball
exercise

40

Aerobic:
walking

DemarkWahnefried,
2008,(49)

I = 26
C = 29

Breast

≥3

Targ,
2002,(50)

I = 74
C = 60

Breast

1

Mutrie,
2007,(51)

I =101
C =102

Methodological Characteristics
Depression
PEDro Score
Measure

exercise

Weight
training: 1 set,
12‒15 reps

Lee, 2010,(48)

Type

Duration
(wk)

Breast

3

Weight
training: Light
(<40% 1-RM)

n/a

50‒75%
HRmax
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Weight
training of
shoulder
muscle
groups
Aerobic
training;
walking

≥30

Weight
training:
elastic band,
medicine ball
exercise

12

HADS

6

90

Yoga

12

POMS

6

45

Walking,
cycling,
aerobics,
strength
exercises

12

BDI

9

First Author,
Year,
Reference

Clinical Characteristics
Type of
Sample Size
Cancer

Exercise Characteristics
Freq
Intensity
-1
(d∙wk )

Time (min∙
-1
session )

Type

Duration
(wk)

Methodological Characteristics
Depression
PEDro Score
Measure

Latka,
2009,(52)

I = 37
C = 38

Breast

5

60‒80%
HRmax

30

Walking

24

CES-D

7

Patel,
2004,(53)

I = 43
C = 19

Breast

1

n/a

90

Yoga

12

POMS

6

Vadiraja,
2009,(54)

I = 44
C = 44

Breast

3

n/a

60

Yoga

6

HADS

8

McClure,
2010,(55)

I = 16
C = 16

Breast

7

Low‒moderat
e intensity

17

Arm flexibility
exercise

17

BDI

6

12

POMS

7

Pinto,
2003,(56)

I = 12
C = 12

Breast

3

60‒70%
HRmax

50

Treadmill
walking, arm
cycling,
stationary
cycling,
rowing

Mock,
1997,(57)

I = 22
C = 24

Breast

4‒5

Self-paced

20‒30

Walking

6

SAS

7

Danhauer,
2009,(58)

I = 13
C = 14

Breast

1

n/a

75

Yoga

10

CES-D

6

Cadmus,
2009,(59)
(IMPACT)

I = 25
C =25

Breast

5

60‒80%
HRmax

30

Not-specified

24

CES-D

8

Drouin,
2005,(60)

I = 13
C=8

Breast

5

50‒70%
HRmax

20‒45

Treadmill
walking

7

POMS

7

Chandwani,
2010,(61)

I = 30
C = 31

Breast

2

n/a

60

Yoga

6

CES-D

6

Vito, 2007,(62)

I =13
C = 12

Breast

2

n/a

90

Yoga

8

POMS

8

Payne,
2008,(63)

I =10
C = 10

Breast

4

Moderate
intensity

20

Walking

12

CES-D

7

Mock,
1994,(64)

I=9
C=9

Breast

≥3

Self-paced

30

Walking

6

SAS

7
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First Author,
Year,
Reference
Eyigor,
2010,(65)

Clinical Characteristics
Type of
Sample Size
Cancer
I = 27
C = 25

Breast

Exercise Characteristics
Freq
Intensity
-1
(d∙wk )
3

Time (min∙
-1
session )

Type
Pilates

8

BDI

5

16

CES-D

7

8

BDI

7

60

Aerobic:
Stationary
cycling
Resistance:
Free weights,
ankle weights

4‒6

HADS

8

12

Walking

3

POMS

7

20‒30

n/a

Methodological Characteristics
Depression
PEDro Score
Measure

Duration
(wk)

Prostate Cancer
Culos-Reed,
2010,(18)

I = 53
C = 47

Prostate

3‒5

moderate

60

Monga,
2007,(66)

I = 11
C = 10

Prostate

3

65% HRreserve

30

Walking,
resistance
exercise
Treadmill
walking

Leukemia

Jarden,
2009,(68)

I = 21
C = 21

Chang,
2008,(69)

I = 11
C = 11

50‒75%
HRmax
Leukemia

1
1‒2 sets,
10‒12 reps

Leukemia

5

60‒110 bpm

Lymphoma
Courneya,
2009,(17)

I = 60
C = 62

Lymphoma

3

50‒75%
V02peak

20‒45

Recumbent
cycle
ergometer

12

CES-D

8

Cohen,
2004,(70)

I = 20
C = 19

Lymphoma

1

n/a

60

Yoga

7

CES-D

7

Courneya,
2003,(67)

I = 69
C = 33

3‒5

65‒75%
HRmax

Walking

16

CES-D

9

Colorectal Cancer
Colorectal

20‒30

NOTE: I, Intervention (exercise group); C, control group
CES-D, Center for Epidemiologic Studies Depression scale; POMS, Profile Of Mood States; BDI, Beck Depression Inventory; HADS, Hospital Anxiety and
Depression Scale; SAS, Social Anxiety Scale.
-1
HRmax, maximum heart rate; HRR, heart rate reserve; V02peak, maximal oxygen consumption (ml∙kg∙min ); bpm, beats per minute; 1-RM, one-repetition maximum
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Table 5. Bivariate moderator intervention characteristics related to depression reduction for all cancer survivors. Supplementary.
Study dimension and levela
d+ (95% CI)c
βd
P
Theory
None
-0.06 (-0.15, 0.03)
0.26
0.01
Psychological
-0.26 (-0.39, -0.13)
Supervision of exercise
Supervised
-0.22 (-0.32, -0.13)
0.37
0.002
Non-supervised
0.07 (-0.06, 0.21)
Non-Hispanic white, %
24
-0.34 (-0.52, -0.17)
0.06
0.01
99
-0.92 (-1.55, -0.29)
Time since diagnosis, mo
2.8
-0.17 (-0.29, -0.04)
0.35
0.02
73.0
0.39 (-0.21, 1.00)
Accumulated weekly volume
PEDro = 5 × 90 min∙wk-1
-0.19 (-0.43, 0.06)
-0.25
0.03
of aerobic exercise, min∙wk- PEDro = 5 × 150 min∙wk-1
-0.02 (-0.26, 0.22)
1
PEDro = 10 × 90 min∙wk-1
0.05 (-0.24, 0.35)
PEDro methodological
-1
PEDro
=
10
×
150
min∙wk
-0.35
(-0.61, -0.08)
score
e
Age , y
39
0.22 (-0.04, 0.47)
0.70
0.001
51
-0.19 (-0.27, -0.10)
69
0.12 (-0.31, 0.54)
NOTE: Weighted mean effect size values (d+) are negative when the exercise
intervention was successful in reducing depression compared to the control
group.
a
Levels represent values of interest of each moderator.
b
k, For categorical variables, k denotes number of effect sizes in each group. For continuous variables, k denotes
total observations.
c
bivariate d+ (95% CI) were calculated using fixed-effects models.
d
β values are standardized.
e
Quadratic trend including linear component.
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Table and Figure titles and footnotes (Supplementary):
Table 4. (Supplementary Material) Clinical, exercise and methodological
characteristics of included studies
NOTE: I, Intervention (exercise group); C, control group
CES-D, center for epidemiologic studies-depression; HADS, hospital anxiety &
depression; POMS, profile of mood states; BDI, Beck depression inventory; SAS,
system assessment scales (100-millimeter axis)
HRmax, maximum heart rate; HRR, heart rate reserve; V02peak, maximal oxygen
consumption (ml∙kg∙min-1); bpm, beats per minute; 1-RM, one-repetition
maximum

Table 5. (Supplementary Material) Bivariate moderator intervention
characteristics related to depression reduction for all cancer survivors
NOTE: Weighted mean
effect size values (d+) are
negative when the
exercise intervention was
successful in reducing
depression compared to
the control group.
a

Levels represent values of interest of each moderator.

b

k, For categorical variables, k denotes number of effect sizes in each group. For

continuous variables, k denotes
total observations.
c

bivariate d+ (95% CI) were calculated using fixed-effects models.
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β values are standardized.

d

e

Quadratic trend including linear component.
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Chapter 5 – Discussion
This thesis includes two studies examining the efficacy of exercise on cancerrelated fatigue (CRF) (1) and depression (2) among adult cancer survivors. In
this concluding chapter, the specific aims and hypotheses of these studies along
with the most relevant findings are reviewed. Then, the clinical significance and
the translation of the findings into clinical practice regarding the Ex Rx among
cancer survivors are discussed.

Lastly, directions for future research and a

concluding summary are provided.
Specific Aims & Hypotheses
Specific Aim 1: To meta-analyze the literature to determine the efficacy of
exercise on reductions in CRF and depression among cancer survivors.
Hypothesis 1: Cancer survivors engaging in exercise would demonstrate
statistically significant reductions in CRF and depression compared to cancer
survivors receiving standard care.

Cancer survivors engaging in exercise

experienced statistically significant reductions in CRF and depression when
compared to cancer survivors receiving standard care.
Specific Aim 2: To meta-analyze the literature to examine the influence of the
frequency, intensity, time and type (FITT) components of the Ex Rx on reductions
in CRF and depression among cancer survivors.

Hypothesis 2: FITT

components of Ex Rx would modulate the magnitude of the reduction in CRF and
depression among cancer survivors. The largest reductions in CRF occurred
when cancer survivors performed resistance training (i.e., weight training). CRF
reductions occurred in a dose response fashion with resistance exercise such
that as intensity of resistance exercise increased, so did reductions in CRF. In
contrast, the largest reductions in depression occurred when cancer survivors
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performed aerobic exercise. Depression reduction occurred in dose-response
fashion with aerobic exercise such that as weekly minutes of aerobic exercise
increased, so did reductions in depression, a finding observed in higher quality
trials.

Moreover, larger reductions in depression occurred with supervised

exercise.
Specific Aim 3: To meta-analyze the literature to examine the influence of
patient clinical characteristics on reductions in CRF and depression among
cancer survivors.

Hypothesis 3: Clinical characteristics of cancer survivors

would modulate the magnitude of the reduction in CRF and depression resulting
from exercise. Subgroup analysis identified breast and prostate cancer survivors
performing exercise significantly reduced CRF compared to breast and prostate
cancer survivors receiving standard care. However, only breast cancer survivors
performing exercise significantly reduced depression compared to other all types
of cancer survivors receiving standard care.
Age moderated the magnitude of the exercise-induced reductions in CRF
and depression. Interestingly, contrasting trends emerged with respect to age of
cancer survivors performing exercise and the magnitude of CRF and depression
reduction. Age of cancer survivors performing resistance exercise was positively
correlated with CRF reduction such that older cancer survivors reduced their
CRF levels to greater levels than younger cancer survivors. Whereas cancer
survivors between the ages of 47–62 yr engaging in aerobic exercise reduced
their depression levels to greater levels than those <47 or >62 yr.
Specific Aim 4: To meta-analyze the literature to examine the influence of the
interactions among FITT components of Ex Rx and patient clinical characteristics
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on reductions in CRF and depression among cancer survivors. Hypothesis 4:
Interactions among FITT components of Ex Rx and patient clinical characteristics
will modulate the magnitude of reduction in CRF and depression among cancer
survivors.

This hypothesis was not supported, as we identified no interactions

among the Ex Rx FITT components and patient clinical characteristics on
reductions in CRF and depression among cancer survivors.
Other findings
Exercise interventions using behavioral change strategies to develop and guide
cancer survivors through the exercise intervention were more efficacious in
reducing CRF than exercise interventions not developed or guided by a
behavioral change model.
The magnitude of exercise-induced CRF reduction was moderated by the
methodological quality of the exercise intervention assessed by the PEDro
methodological score (3). There was a significant interaction between the PEDro
methodological score and intensity of resistance exercise prescribed. Exercise
interventions of lower methodological quality were efficacious in reducing CRF
when

they

prescribed

low

or

moderate

intensity

resistance

exercise.

Interventions of higher methodological quality were efficacious in reducing CRF
only when they prescribed moderate-intensity resistance exercise.
There was a significant interaction between the PEDro methodological
score and weekly volume of aerobic exercise. Exercise interventions of lower
methodological quality were not efficacious in reducing depression at any weekly
volume of aerobic exercise, whereas interventions of higher methodological
quality were efficacious in reducing depression with larger weekly volumes of
aerobic exercise.
Physiologic specificity of exercise and modulation of CRF and depression
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The efficacy of exercise to reduce CRF and depression emerged to be modality
(or type of exercise) specific. Resistance training reduced CRF in dose response
fashion, whereas aerobic exercise reduced depression in dose response fashion.
Despite the unknown etiology of CRF and depression among cancer survivors,
several hypotheses are suggested (4, 5).
CRF associates with variety of physiologic alterations occurring with
cancer and cancer treatment. These alterations include decreases in muscle
mass and muscle strength, and marked increases in pro inflammatory cytokines,
specifically interleukin-6 (IL-6), IL-1β, and tumor necrosis factor-α (TNF- α) (5).
Interestingly, resistance exercise elicits increases in muscle mass, muscle
strength, and a cascade of cytokine responses occurring in dose response
fashion with exercise intensity among apparently healthy persons (6). During
resistance exercise there is an up regulation of anti-inflammatory cytokines,
specifically IL-6 and IL-10 (6, 7). This increase in anti-inflammatory cytokines
results in subsequent down regulation of pro-inflammatory cytokines including
TNF-α and IL-1β, postulated to result in diminished levels of CRF (5, 7).
Appropriately, this meta-analysis found resistance training reduced CRF in dose
response fashion, fully supporting the cytokine dysregulation hypothesis of CRF
proposed by Al-Majid (5). Moderate intensity resistance training elicits similar
cytokine responses in prostate cancer survivors resulting in diminished levels of
CRF providing additional evidence for this hypothesis in a randomized controlled
trial (8, 9).
The specific etiology of depression remains unclear despite 50 yr of
investigation (10). Several hypotheses exist including monoamine imbalance,
hypothalamic pituitary axis dysregulation, and depletion of β-endorphins in the
brain (10, 11). Monoamine imbalance is the most widely proposed hypothesis
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relating to depression. Monoamines (serotonin, noradrenaline, and dopamine)
are critical to the efficacy of anti-depressant medication (10). The function of
anti-depressants is to retard the rate of monoamine degradation in the body (10).
This yields higher bioavailability of monoamines, subsequently increasing their
concentration at synaptic junctions in the brain postulated to result in lower levels
of depression (10). The physiologic response to anti-depressant medication is
similar to that of aerobic exercise (10, 12); increasing the bioavailability of
monoamines (12). Acute and chronic aerobic exercise increases monoamine
concentrations above pre exercise levels, and above those achieved with heavy
resistance training (13). This makes aerobic exercise an optimal modality to
improve monoamine concentration among those with depression. An acute bout
of aerobic exercise increases monoamine concentrations from pre exercise
levels, and chronic aerobic exercise increases monoamine concentration from
acute exercise levels (12). This monoamine response makes chronic aerobic
exercise training an efficacious intervention for the management of depression.
Appropriately, we found aerobic exercise reduced depression in dose response
fashion; larger volumes of weekly aerobic exercise were more efficacious in
reducing depression among cancer survivors. The finding that aerobic exercise
in dose response was more efficacious than strength training to reduce
depression supports the monoamine hypothesis proposed by others (10-12). A
randomized controlled trial examining aerobic exercise and biomarkers
associated with depression would provide additional evidence for this hypothesis.
Clinical significance of the findings and their translation into clinical
practice
The current Ex Rx recommendations for cancer survivors suggest a general
health fitness program focusing on accruing ≥150 min∙wk-1 of aerobic exercise,
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complimented with two days of resistance exercise, and flexibility training on
days of non-exercise (14, 15).

Ex Rx guidelines from the ACSM expert

consensus for cancer survivors are consistent with the recommendations made
in 2008 for physical activity among healthy Americans (16).
The current Ex Rx for cancer survivors was not developed and tailored for
symptom management. Rather, the generic Ex Rx implements a broad range of
modalities of light to moderate intensities, likely providing improvements in health
related components of physical fitness including aerobic capacity, muscular
strength and endurance, body composition, and flexibility, but providing no
insight for symptom management. The current Ex Rx recommendations suggest
a ‘one size fits all’ approach to exercise and symptom management. The expert
panel did not provide symptom specific Ex Rx recommendations due to the
heterogeneity of results in symptom improvements relating to the varying doses
of exercise prescribed (14). The lack of evidence regarding symptom outcomes
was a noted research gap warranting further investigation. The expert panel
acknowledged,

“The

existent

literature

is

insufficient

to

assist

fitness

professionals with the specifics required to ensure that cancer survivors receive
safe and effective exercise prescriptions” (14).
This thesis provides support for the dose-response effects of exercise on
CRF and depression. More importantly, the findings from this thesis provide
evidence for hypothesis driven prospective randomized control trials to test the
dose-response effect of exercise on CRF and depression. Evidence from future
randomized trials may confirm the findings of this meta-analysis, suggesting
refinement of the current Ex Rx based upon magnitude of symptoms experienced
during and after treatment.
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The findings of this meta-analysis indicate cancer survivors reporting CRF
as their chief complaint may reap the largest benefits in CRF reduction by
engaging in a progressive, supervised, strength training program, complimented
by aerobic and flexibility exercises. Strength training should begin with little to no
weight and progress as appropriate. Schmitz et al. (17, 18) demonstrated breast
cancer survivors, with and at-risk for lymphedema, have been able to participate
in slowly progressive weight training with no maximum intensity restrictions,
including one repetition maximum testing (1-RM; the maximum amount of weight
lifted one time). This trial used weighted Velcro straps or no weight at all for two
sets of each exercise of 10 repetitions per set. After being able to perform two
additional repetitions, for two sets, for two consecutive workouts, the resistance
increased by the smallest possible increment. This indicates slowly progressive
resistance training is safe for breast cancer survivors with and at risk for
lymphedema, reduces limb swelling, reduces self-reported lymphedema
symptoms, improves quality of life and body image, and reduces CRF.
Conversely, the findings of this meta-analysis suggest cancer survivors
reporting depression as their chief complaint may reap the largest reductions in
depression by engaging in a structured, supervised, aerobic exercise program
with the primary goal of achieving large weekly volumes of aerobic exercise,
complimented by strength and flexibility exercise.

Breast cancer survivors

accrued ≥150 min∙wk-1 of aerobic treadmill exercise in 12 wk (19), and 225
min∙wk-1 over 24 wk of training. Survivors performed 3–5 d∙wk-1 treadmill walking
for 15–20 min∙d-1 with small weekly increments (i.e., 5–10 min) until 150 or 225
min∙wk-1 was achieved (20). These trials provide a model for clinicians to follow
when prescribing progressive aerobic exercise. However, accruing ≥150 min∙wk1

of aerobic exercise may take longer than 12 wk if pre-diagnosis physical activity
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levels were low and other comorbidities exist (i.e., obesity). Jones et al. (21)
provides a schematic to aid the clinician in identifying the appropriate dose of
exercise to prescribe by assessing previous and current exercise levels of
patients. The schematic provides the appropriate frequency, intensity, time, and
type of exercise recommended by the current ACSM Ex Rx (4, 11). Clinicians
and health fitness professionals should always weigh the risk to benefit ratio
when prescribing larger or more intense doses of exercise to their patients and
clients.
The ACSM expert panel acknowledged the interaction of age with
exercise training is of special interest as many cancer survivors are older
because they now living with rather than dying from cancer (14). We quantified
the moderating effects of age and the exercise-induced reductions in CRF and
depression.

Cancer survivors reduced CRF to the greatest magnitude with

increasing age, whereas cancer survivors age 47–62 yr reduced depression to
the greatest magnitude (1, 2). Age modulates CRF and depression differently
among different types of cancer survivors when performing exercise, suggesting
age may be a characteristic considered when developing an Ex Rx for symptom
management.
Future Research
This thesis provides continued evidence supporting the efficacy of exercise
training among cancer survivors. However, many research questions remain.
Other clinically relevant side effects of cancer or cancer treatment such as
anxiety, nausea, and pain and their response to exercise training warrant
continued investigation. Existent literature has examined the efficacy of exercise
training among breast cancer survivors (22). Future research should investigate
the safety and efficacy of exercise training on other common forms of cancer
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including lung, colorectal, prostate, and ovarian cancers. Furthermore, a majority
of cancer survivors participating in exercise training studies are Caucasian, nonHispanic whites (14).

Noted in the expert consensus statement (14), future

research needs to examine the efficacy of exercise training among racial and
ethnic minority groups as well as those of low socioeconomic status. Future
trials should examine exercise training among cancer survivors presenting with
co-morbidities such as cardiac conditions, obesity, metabolic, and bone
disorders.
To verify our findings, a large, well-powered, randomized controlled trial
examining the efficacy of the specific doses and modalities of exercise found to
be efficacious in reducing CRF and depression among cancer survivors should
be conducted. For example, a trial designed to test our findings relating to CRF
reduction would employ a four arm randomized design with 42 subjects per arm
(N=168). This sample would provide 80% power, and two-sided α = 0.05 to
detect a reduction in CRF. Participants would be randomized to one of four
groups: 1) moderate intensity resistance training (60–80% 1-RM; 2 sets; 8–12
repetitions; 3 d∙wk-1); 2) moderate intensity aerobic exercise (40–60% V02peak, 3
d∙wk-1); 3) a combination of arms aerobic and strength exercise; or 4) placebo
wait list control.

This trial would compare different modalities of exercise to

reduce CRF. Once the optimal modality of exercise is identified, other program
variables manipulated in similarly designed trials might include frequency,
intensity, and time of exercise.

A similar randomized study design could also

investigate depression as a primary outcome to elucidate efficacious modalities
of exercise.
Conclusion
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This meta-analysis examined the magnitude of the exercise induced reductions
in CRF and depression among cancer survivors.

Additionally, this thesis

investigated the Ex Rx and clinical patient characteristics moderating the
magnitude of the exercise induced responses in CRF and depression among
cancer survivors. This thesis provides evidence that resistance training reduces
CRF, and aerobic training reduces depression among cancer survivors. Both
CRF and depression responding to exercise training in dose response fashion.
This research highlights the importance of the continued development of
symptom-specific Ex Rx among cancer survivors. The findings from this thesis
provide a framework to begin tailoring the FITT components of the Ex Rx for
symptom specific management of cancer survivors, whereas prior exercise
interventions have prescribed a ‘one size fits all’ approach to exercise and
symptom management. In accordance with current Ex Rx guidelines, all cancer
survivors should strive to avoid inactivity if at all possible (14). Cancer survivors
are encouraged to discuss the safety, feasibility, and efficacy of beginning an
exercise program with their oncologist or primary care physician.

101

References
1. Brown JC, Huedo-Medina TB, Pescatello LS, Pescatello SM, Ferrer RA,
Johnson BT. Efficacy of exercise interventions in modulating cancer-related
fatigue among adult cancer survivors: A meta-analysis. Cancer Epidemiol
Biomarkers Prev. 2011 Jan;20(1):123-33.
2. Brown JC, Huedo-Medina TB, Johnson BT, et al. The efficacy of exercise
interventions on depression among cancer-survivors: A meta-analysis. Cancer.
[In Review].
3. Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of
the PEDro scale for rating quality of randomized controlled trials. Phys Ther.
2003 Aug;83(8):713-21.
4. al-Majid S, McCarthy DO. Cancer-induced fatigue and skeletal muscle
wasting: The role of exercise. Biol Res Nurs. 2001 Jan;2(3):186-97.
5. Al-Majid S, Gray DP. A biobehavioral model for the study of exercise
interventions in cancer-related fatigue. Biol Res Nurs. 2009 Apr;10(4):381-91.
6. Izquierdo M, Ibanez J, Calbet JA, et al. Cytokine and hormone responses to
resistance training. Eur J Appl Physiol. 2009 Nov;107(4):397-409.
7. Jager A, Sleijfer S, van der Rijt CC. The pathogenesis of cancer related
fatigue: Could increased activity of pro-inflammatory cytokines be the common
denominator? Eur J Cancer. 2008 Jan;44(2):175-81.
8. Galvao DA, Nosaka K, Taaffe DR, et al. Endocrine and immune responses to
resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis.
2008;11(2):160-5.
9. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance
and aerobic exercise program reverses muscle loss in men undergoing androgen
suppression therapy for prostate cancer without bone metastases: A randomized
controlled trial. J Clin Oncol. 2010 Jan 10;28(2):340-7.
10. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature.
2008 Oct 16;455(7215):894-902.
11. Craft LL, Perna FM. The benefits of exercise for the clinically depressed.
Prim Care Companion J Clin Psychiatry. 2004;6(3):104-11.
12. Arida RM, Naffah-Mazzacoratti Mda G, Soares J, Cavalheiro EA. Monoamine
responses to acute and chronic aerobic exercise in normotensive and
hypertensive subjects. Sao Paulo Med J. 1998 Jan-Feb;116(1):1618-24.

102

13. Raastad T, Glomsheller T, Bjoro T, Hallen J. Changes in human skeletal
muscle contractility and hormone status during 2 weeks of heavy strength
training. Eur J Appl Physiol. 2001 Jan-Feb;84(1-2):54-63.
14. Schmitz KH, Courneya KS, Matthews C, et al. American college of sports
medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports
Exerc. 2010 Jul;42(7):1409-26.
15. Thompson, WR., Gordon, NF., Pescatello LS., editor. ACSM's guidelines for
exercise testing and prescription. 8th ed. Philadelphia, PA: Lippincott, Williams &
Wilkins; 2010.
16. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health:
Updated recommendation for adults from the american college of sports
medicine and the american heart association. Circulation. 2007 Aug
28;116(9):1081-93.
17. Schmitz KH, Ahmed RL, Troxel A, et al. Weight lifting in women with breastcancer-related lymphedema. N Engl J Med. 2009 Aug 13;361(7):664-73.
18. Schmitz KH, Ahmed RL, Troxel AB, et al. Weight lifting for women at risk for
breast cancer-related lymphedema: A randomized trial. JAMA. 2010 Dec
22;304(24):2699-705.
19. Irwin ML, Alvarez-Reeves M, Cadmus L, et al. Exercise improves body fat,
lean mass, and bone mass in breast cancer survivors. Obesity (Silver Spring).
2009 Aug;17(8):1534-41.
20. Ballard-Barbash R, Hunsberger S, Alciati MH, et al. Physical activity, weight
control, and breast cancer risk and survival: Clinical trial rationale and design
considerations. J Natl Cancer Inst. 2009 May 6;101(9):630-43.
21. Jones LW, Eves ND, Peppercorn J. Pre-exercise screening and prescription
guidelines for cancer patients. Lancet Oncol. 2010 Oct;11(10):914-6.
22. Ferrer RA, Huedo-Medina TB, Johnson BT, Ryan S, Pescatello LS. Exercise
interventions for cancer survivors: A meta-analysis of quality of life outcomes.
Ann Behav Med. 2011 Feb;41(1):32-47.

103

Appendix — Systematic Data Extraction Form
Exercise and Depression in Cancer Patients and Survivors

Study Selection Criteria
Studies must have an intervention intended to affect physical activity behavior in
individuals who have been diagnosed with cancer (thus studies with no
manipulation (or studies with a manipulation but in which researchers determined
the manipulation was ineffective and separated the group for analysis based on
self-selected exercise), studies with interventions intended to affect another
behavior in cancer survivors, or interventions intended to affect behavior in
relatives or friends of cancer survivors are excluded).
1. target adult (over age 18) cancer survivors (excluding
studies that target pediatric and adolescent cancer
survivors)
2. include an appropriate comparison (excluding studies with
self-selected intervention/ control groups; does not exclude
pre-test/ post-test design, studies that compare a pre-test
control group measure to a post-test intervention group
measure; non-equivalent control group designs or other
designs that do not use randomization but have
appropriate comparison data).
3. include non-independent data (excluding studies that are a
re-analysis of data in studies already included in the
analyses, and studies that use the same participants as
studies already included in the analyses).
4. include appropriate quantitative dependent variables
(depression, anxiety, physiological, and exercise
adherence measures)
5. provide requisite statistical information to allow for
calculation of effect size.
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PHYSICAL ACTIVITY IN CANCER SURVIVORS META-ANALYSIS CODING
FORM
24 May 2010
Note: Throughout, use “.” to indicate missing information.
_____
Coder (Becky = 1, Blair = 2, Linda = 3, Stacey = 4, Justin = 5,
Shannon = 6)

(V1)

Study Information (this page should be coded separately; complete the
remainder coding pages later, once all information but methods have been
removed from the folder)
(V2)

__ __ __ Study ID #

(V3)

__ __ __ __ Publication year (consider this missing if unpublished)

(V4)

__ __ __ __ Estimated year of data collection (earliest date for data
collection or manuscript submission/publication; if
unpublished and date unknown, use year manuscript was
acquired; for dissertation or thesis, use year)

(V5)

_____

Language of publication:
1=English
3=German
2=French
4=other, specify:
_____________________________

(V6)

_____

Source:
1=journal 2=book 3=thesis/dissertation
paper 5=unpublished document
6=other published document; specify:
__________________________

(V7)

_____

Full APA citation:

4=conference

Dominant theoretical perspective explicitly stated:
1=Theory of Reasoned Action/Planned Behavior (Fishbein,
Ajzen, etc.)
2=Social cognitive/Self-efficacy/Social learning (Bandura,
etc.)
3=Transtheoretical Model (“stages of change”, Prochaska &
DiClemente)
4=Health Belief Model (HBM, Rosenstock et al.)
5=Information Motivation Behavioral Skills Model (IMB,
Fisher & Fisher)
6=Protection-Motivation theory (Rogers, etc.)
7=Self-perception (or –persuasion)/Cognitive dissonance
(Aronson, Bem, Festinger cited, “hypocrisy” approaches)
8=Social Action Theory (Ewart)
9=Social Diffusion
(Rogers)
10=Conservation of Resources (Hobfall) 11=Payne
Theoretical Model
12=Levine Conservation
13=Roy Adaptation
Model
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14= 5 A’s of Exercise Adoption (ACSM)
___________________________

15=Other, specify:

_____
Type of clinical exercise recommendation
followed/prescribed:
1= National Comprehensive Cancer Network
Recommendations (NCCN)
2= American College of Sports Medicine Exercise Rx for
cancer survivors
3= American College of Sports Medicine Exercise Rx for
(healthy)
4= Australian Association of Exercise and Sport Science
Exercise (AAESS)
5= Other clinical recommendation;
specify:____________________
(V8)

Sample Characteristics
Notes on intervention within study relevant to coding (if more than
one intervention in study)
___________________________________________________________
___________

(V9)

(V10) _____
(V11)
(V12)
(V13)
(V14)
(V15)
(V16)

____
____
____
____
____
____

Ethnicity reported?

1 = yes; 0 = no

Proportion White; if whole number available:______
Proportion Black; if whole number: ______
Proportion Latino/Hispanic; if whole number: ______
Proportion Caribbean; if whole number: _____
Proportion Asian; if whole number: ______
Proportion Mixed/other; if whole number: ______

(V17) _____

Education reported? 1 = yes; 0 = no

(V18) _____

Proportion high school only: _____

(V19) _____

Proportion college only: _____

(V20) _____

Proportion graduate school:_______

(V21) ___

SES
0 = Not given
1= Low
2 = Middle
3 = High

(V22) _____

Region of sample
1=American city: __________________
2=other U.S. general region (city not specified):
__________________
3=Canada (city: _______________________)
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4=Europe (city: _______________________)
5=South or Central America, Mexico, Caribbean (city:
_______________________)
6=Africa (city: _______________________)
7=Asia (city: _______________________)
8=Australia (city: _______________________)
(V23) _____

(V24) ___
(V25) ___

City size
0=not given
1=rural (< 10 thousand people)
2=small (10 – 100 thousand people)
3=medium (100 thousand – 1 million people)
4=large (more than 1 million people)
Zip Code (US Only) _______
City: ______________________

(V26) _____
(V27) _____

Average age of sample ___________
SD for age _____________________

(V28) _____

Population
1=school or college
2=community, not currently institutionalized; specify source (e.g.,
cancer clinic including University cancer treatment
facilities)_____________________________________________
___________
3=institutionalized; specify source (e.g., inpatient cancer
treatment center; currently hospitalized):
______________________________________________
__________
0=not given

Risk Characteristics
(V29) _____

Proportion of sample overweight; if whole number:

_______
(V30) _____

Average minutes of exercise at baseline: ______

(V31) ____

Type of cancer:
1=breast
2=prostate
3=head and neck
4=colorectal
5=skin
6=leukemia
7=myeloma
8=lymphoma
9=gastrointestinal
10=lung
11=ovarian
12=pancreatic
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13=bladder
14=endometrial
15=kidney/renal
16=appendix
17=cervical
18=testicular
19-brain
0=combination (list numbers): _______
(V32) _____

Average Length since cancer diagnosis (in months):

______
(V33) _____

Proportion of participants in remission

(V34) _____

Treatment (if more than one, indicate percentages)
0=none currently
1=chemotherapy
2=radiation
3=surgery
4=transplant
5=hormones
other (specify): _______
Proportion of participants under chemotherapy in the

(V35) _____

past
(V36) _____
(V37) _____
(V38) _____

Proportion of participants currently under chemotherapy
Proportion of participants under radiation in the past
Proportion of participants currently under chemotherapy

(V39) _____
(V40) _____
(V41) _____

Average length under treatment
Average length under non treatment
Proportion of the sample under drug treatment (specify:
___________________)
(V42) _____
Proportion of the sample with other diseases (specify:
___________________)
(V43) _____
Proportion of overweight sample
(V44) _____
Proportion of the sample under drug treatment (specify:
___________________)
(V45) _____
Proportion of smokers on the sample

Design & Measurement
(V46) _____

Recruitment method
1=self-selected from community (via flyers, community
centers, etc.)
2=recruited through clinical contact (cancer clinic, etc.)
3=recruited through hospital
4=other (specify): __________
0=not given

(V47) _____

Type of control group used
True control groups
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1=random assignment of individuals to conditions
2=matching individuals on some variable (specify:
__________________________), then random
assignment
3=random assignment of some groups of individuals (e.g.,
classrooms)
Nonequivalent control groups (comparison group)
4=tried to ensure some comparability of the nonequivalent control group
by: (e.g., comparing on some var):
________________________________________________________
______________
5=the nonequivalence of comparison group was not
addressed
(V48) _____
(V49) _____
(V50) _____

Number of follow-ups: _______
Interval of follow-ups: _______
Scale used to measure depression:
___________________________________________
(V51) _____
Scale used to measure anxiety:
_______________________________________________
(V52) _____

(V53) _____

Control for social-desirability bias in self-report
Anonymity attempted (1 if unclear)
1=no 2=yes 0=no measures self-report
Low reactivity of measure completion (1 if unclear)
1=no; intervention and measurement staff were the same
&/or face-to-face interviews used
2=yes; used different personnel for intervention and
measurement, and measurement technique not highly
reactive (written questionnaires used rather than oral
responses)
0=no self report

Experimental (Intervention) Condition Details
(V54) _____
(V55) _____

Length of intervention in weeks: ________
Aerobic/ Cardiovascular Activities (in METS as defined in

excel file)
(V56) _____

Resistance/ Strength Activities (in METS as defined in

excel file)
(V57) _____

Flexibility
0=no
1=yes
(V58) _____
Description of exercise based on report (take description
of exercise):
_________________________________
(V59) ____
Structure of intervention
1=incentive (e.g., payment based on sessions attended)
2=supervised (group exercise sessions provided)
3=unsupervised (education, etc. provided, but participants
expected to exercise on own)
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(V60) ____

(V61) _____

4=lifestyle activity
Intervention for weight loss or weight gain:
1=loss
2=gain
3=neither
Type of intervention
0=exercise only
1=exercise and diet
2=exercise and diet other (specify): _________
3=exercise and other (specify): _______

(V62) _____

Level of intervention used in the study
1=primarily one-on-one (e.g., individual counseling sessions;
individuals each exposed to persuasive messages alone
or in a group)
2=small group processes (interaction between leader and
group, and group members)
3= small group processes (interaction among the group
members, there is not leader)
4=single community (e.g., street studies with mix of media
and face-to-face interventions)
5=multiple communities (e.g., mix of media and face-to-face
interventions)

(V63) _____

Number of experimental conditions for which effect sizes
will each be calculate (if some experimental conditions in
the study are omitted here, explain why they are excluded:
_______________________________________________)

(V64) _____

Number of DVs for which effect sizes will be calculated
for each experimental condition

Experimental condition ______________________________ (give label for
condition, e.g., that used in the article)
Intervention Details for INTERVENTION GROUP: (use label from study):
______________________________
(V65) _____ Number of sessions
(V66) _____ Number of minutes for each session; if varies, report
average; specify each: ___________________
(V67) _____ Average size of participant group for a session
(V68) _____ Number of facilitators/experimenters per group
(V69) _____ Training of session leaders or speakers

1=professionals—formal matriculation, licensing, or degree
2=paraprofessionals
3=peers
0=not given
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(V70) _____ Content of the intervention (NOT the measures) matched to

sample
0=no mention of elicitation research, focus groups to
determine relevant issues for this population
1=mention of informal assessment of determining content
through some kind of elicitation research, or pilot testing of
content
2=systematic formal assessment of appropriate content—
e.g., focus groups with content analyzed, or previous
paper analyzing results of elicitation research
3=not reported
(V71) _____

Number of participants who began study (in
experimental group)
(V72) _____
Final N in experimental group (after attrition—use largest
available)
(V73) _____
Number of participants who did not complete the study
due to cancer-related mortality
(V74) _____
Number of participants who did not complete the study
due to cancer-related illness/ complications
(V75) _____
Proportion of women in sample; if whole number
available: ______
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CONTROL CONDITIONS: USE THE FOLLOWING SCHEME:
Codes for control conditions
1=wait-list/no treatment/no contact control group
2=exercise education only
3=irrelevant content (+/- education), matched for time/contact to
experimental condition
4=brief form of experimental condition describe: ___________________
5=other kind of comparison condition; specify:
______________________

(V76) _____

Number of control/comparison groups in the study (do not
count any that are reasonably considered experimental
conditions); describe each:

(V77) _____
(V78) _____

Number of participants n control group
Final Control N (after attrition—use largest available at

posttest)
(V79) _____

Number of participants who did not complete the study
due to cancer-related mortality
(V80) _____
Number of participants who did not complete the study
due to cancer-related illness/
complications
(V81) _.___
Proportion of women in sample; if whole number
available: ______
(V82) _.___
Proportion men in sample; if whole number: _______

Criteria for selecting control groups for effect size calculations:
If control condition type 1 is available, use it; otherwise use group 2 to
calculate effect sizes; all others should be considered as experimental
conditions. If neither control type 1 or 2 is available, use the control condition
corresponding to the lowest numerical value above (e.g., use 3 if available,
otherwise 4, otherwise 5).
(V83) _____ Using the key above, list the code for the control group

used in effect sizes
Content of Control Group (in calculating time, do not include
measurement completion time when possible)
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(V84) _____ Number of sessions in control group
(V85) _____ Number of minutes for each session; if varies, report

average (estimate if necessary); specify each:
__________________________________
(V86) _____ Average size of participant group for a session (blank if no
contact/wait list)
(V87) _____ Total minutes of exercise information (estimate if
necessary)
(V88) _____ Total minutes of non-exercise education presented (estimated)
1. Eligibility criteria were specified
1 = Yes
0 = No
2. Subjects were randomly allocated to groups (in a crossover study,
subjects
were randomly allocated an order in which treatments were received)
1 = Yes
0 = No
3. Allocation was concealed
1 = Yes
0 = No
4. The groups were similar at baseline regarding the most important
prognostic
indicators
1 = Yes
0 = No
5. There was blinding of all subjects
1 = Yes
0 = No
6. There was blinding of all therapists who administered the therapy
1 = Yes
0 = No
7. There was blinding of all assessors who measured at least one key
outcome
1 = Yes
0 = No
8. Measures of at least one key outcome were obtained from more than
85%
of the subjects initially allocated to groups
1 = Yes
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0 = No
9. All subjects for whom outcome measures were available received the
treatment or control condition as allocated or, where this was not the
case,
data for at least one key outcome was analysed by “intention to treat”
1 = Yes
0 = No
10. The results of between-group statistical comparisons are reported for at
least one
key outcome
1 = Yes
0 = No
11. The study provides both point measures and measures of variability for
at
least one key outcome
1 = Yes
0=No
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